Notes to Financial Statements
Note A – The Company and its Significant Accounting Policies
The Company:
American Bio Medica Corporation (the “Company”) 1) manufactures and sells lateral flow immunoassay tests, primarily for the immediate detection of drugs in urine and oral fluid, 2) provides strip manufacturing and assembly and packaging services for unaffiliated third parties and 3) sells (via distribution) a number of other products related to the immediate detection of drugs in urine and oral fluid, point of care diagnostic products and rapid Covid-19 tests.
Going Concern:
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. For the year ended December 31, 2021 (“Fiscal 2021”), the Company had a net loss of $463,000 and net cash used in operating activities of $673,000, compared to a net loss of $796,000 and net cash used in operating activities of $483,000 for the year ended December 31, 2020 (“Fiscal 2020”). The Company’s cash position increased by $17,000 in Fiscal 2021 and $94,000 in Fiscal 2020. The Company had a working capital deficit of $(1,484,000) at December 31, 2021, compared to a working capital deficit of $(841,000) at December 31, 2020. This increase in working capital deficit is primarily a result of our loans with Cherokee Financial, LLC being classified as long-term debt in Fiscal 2020 and as short term debt in Fiscal 2021, partially offset by the forgiveness of the PPP loan in Fiscal 2021.
As of December 31, 2021, the Company had an accumulated deficit of $23,813,000. Over the course of the last several fiscal years, the Company has implemented a number of expense and personnel cuts, had a salary deferral program, consolidated certain manufacturing operations of the Company, refinanced debt, consummated private placements of shares of Company common stock and entered into an equity line of credit with Lincoln Park Capital Fund, LLC.
From August 2013 until June 2020, the Company maintained a 10% salary deferral program for its sole executive officer, Chief Executive Officer/Principal Financial Officer Melissa Waterhouse. The salary deferral program was initiated by Ms. Waterhouse voluntarily. Another member of senior management participated in the program voluntarily until his retirement in November 2019. After the member of senior management retired, the Company agreed to make payments on the deferred compensation owed to this individual. In Fiscal 2021 and Fiscal 2020, the Company made payments of $20,000 and $57,000, respectively. The deferred compensation owed to this individual was paid in full in May 2021. Once the deferred compensation was paid in full to this individual, the Company began to make payments at the same rate to Ms. Waterhouse given the length of time the amount had been owed and that the last payment (prior to May 2021) made to Ms. Waterhouse was in August 2017. In Fiscal 2021, the Company made payments totaling $33,000 to Ms. Waterhouse. The Company did not make any payments on deferred compensation to Ms. Waterhouse in Fiscal 2020. As of December 31, 2021, the Company had deferred compensation owed to Ms. Waterhouse in the amount of $74,000 and $5,000 in payroll taxes that are due as payments are made to Ms. Waterhouse; for a total of $79,000 in deferred compensation. The Company intends to continue to make payments to Ms. Waterhouse until the deferred compensation is paid in full.
The Company’s current cash balances, together with cash generated from future operations and amounts available under its credit facilities may not be sufficient to fund operations through April 2023. At December 31, 2021, the Company had a Stockholders’ deficit of $(944,000).
The Company’s loan and security agreement and 2020 Term Note with Cherokee for $1,000,000 and $240,000, respectively, expired on February 15, 2022. See Note L – Subsequent Events for more information on the status of the Cherokee loans.
The Company’s line of credit with Crestmark Bank has a maximum availability of $1,000,000; however, the amount available under the line of credit is much lower as it is based upon the balance of the Company’s accounts receivable. As of December 31, 2021, based on an availability calculation, there were no additional amounts available under the Crestmark line of credit because the Company draws any balance available on a daily basis. If sales levels continue to decline, the Company will have reduced availability on the line of credit due to decreased accounts receivable balances. The line of credit with automatically renew on June 22, 2022 for an additional one year term unless notice of termination from the Company is received by Crestmark not less than sixty (60) days prior to the end of the renewal term.
On December 9, 2020, the Company entered into a Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) under which Lincoln Park agreed to purchase from the Company, from time to time, up to $10,250,000 of our shares of common stock, par value $0.01 per share, subject to certain limitations set forth in the Purchase Agreement, during the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, the Company was required to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 (the “Registration Statement”) to register for resale under the Securities Act of 1933, as amended (the “Securities Act”), the shares of common stock issued and sold as well as the shares of common stock that the Company may elect in the future to issue and sell to Lincoln Park from time to time under the Purchase Agreement. In Fiscal 2021, the Company, the Company received gross proceeds of $125,000 from Lincoln Park as an Initial Purchase under the Purchase Agreement. In Fiscal 2021, the Company received gross proceeds of $639,000 for the balance of the Initial Purchase and Regular Purchase under the Purchase Agreement.
In Fiscal 2021, the Company, through its payroll service provider, processed and mailed a Form 941-X to claim an Employee Retention Credit (“ERC”) refund in the amount of $202,000 on qualified wages paid in the first quarter of 2021. Due to a change in the Form 941-X, the payroll service provider did not process and mail the Company’s Form 941-X to claim an ERC refund in the amount of $198,000 on qualified wages paid in the second quarter of 2021 until October 28, 2021. In the middle of the third quarter of Fiscal 2021, the Company began taking the ERC in its current payroll; which reduced payroll by approximately $44,000 in the third quarter of 2021 and $38,000 in the fourth quarter of Fiscal 2021 (until the ERC program was ended early as part of the Infrastructure bill signed into law on November 15, 2021). Given this, the Company did not have to amend its Form 941 for the third quarter of 2021; rather the Form 941 claiming a refund in the amount of $137,000 was filed electronically with the IRS on November 1, 2021 by the Company’s payroll service provider. On December 28, 2021, the Company received its refund for the third quarter of Fiscal 2021 in the amount of $137,000. Shortly before receiving the first refund, the Company spoke with the Internal Revenue Service (“IRS”) to obtain statuses of our filings. It was then that the Company was informed that the IRS did not have record of receiving the Company’s Form 941-X for the first quarter of Fiscal 2021 (which was mailed by the service provider in August 2021). The Company re-sent the Form 941-X for the first quarter of Fiscal 2021 via overnight service on December 31, 2021 and the IRS received it on January 5, 2022. This lack of receipt will result in a delay in receiving the expected refund in the amount of $203,000. Based on our discussion with the IRS, we were expecting the refund payment for the second quarter of Fiscal 2020 sometime in February 2022; however, as of the date of this report, we have not received any further refund payments.
If availability under the Crestmark line of credit, cash received from equity sales under the Lincoln Park Purchase Agreement and/or cash received as refunds under the ERC program are not sufficient to satisfy working capital and capital expenditure requirements, the Company will be required to obtain additional credit facilities or sell additional equity securities, or delay capital expenditures which could have a material adverse effect on the Company’s business. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all.
The Company’s ability to repay its current debt may also be affected by general economic, financial, competitive, regulatory, legal, business and other factors beyond the Company’s control, including those discussed herein. If the Company is unable to meet its credit facility obligations, the Company would be required to raise money through new equity and/or debt financing(s) and, there is no assurance that the Company would be able to find new financing, or that any new financing would be at favorable terms.
The Company’s history of limited cash flow and/or operating cash flow deficits and its current cash position raise doubt about its ability to continue as a going concern and its continued existence is dependent upon several factors, including its ability to raise revenue levels and control costs to generate positive cash flows, to facilitate purchases under the Lincoln Park equity line of credit to operations and/or obtain additional credit facilities. Obtaining additional credit facilities may be more difficult as a result of the Company’s operating losses.
If events and circumstances occur such that 1) the Company cannot raise revenue levels, 2) the Company is unable to control operational costs to generate positive cash flows, 3) the Company cannot maintain its current credit facilities or refinance its current credit facilities, 4) the Company is unable to raise sufficient additional equity or debt financing, or 5) the Company is unable to effect sales under the Lincoln Park Equity Line, we may be required to further reduce expenses or take other steps which could have a material adverse effect on our future performance. The Company’s financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount of or classification of liabilities that might be necessary as a result of this uncertainty.
While the Covid-19 pandemic is seemingly winding down, the Company continues to be impacted by it in the form of material delays, cost increases (in both manufacturing and other business costs), labor shortages and decreased sales orders from customers. The Company is unsure as to how long the Company will continue to be impacted negatively. The extent to which the pandemic may continue to impact the Company’s business, liquidity, results of operations and financial condition will depend on future developments, which are still uncertain and cannot be predicted. If the Company, its customers or suppliers experience (or in some cases continue to experience) business disruptions, the Company’s business, liquidity, results of operations and financial condition are likely to be materially adversely affected, and the Company’s ability to access the capital markets may be limited.
Significant Accounting Policies:
[1] Cash equivalents: The Company considers all highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
[2] Accounts Receivable: Accounts receivable consists of mainly trade receivables due from customers for the sale of our products. Payment terms vary on a customer-by-customer basis, and currently range from cash on delivery to net 60 days. Receivables are considered past due when they have exceeded their payment terms. Accounts receivable have been reduced by an estimated allowance for doubtful accounts. The Company estimates its allowance for doubtful accounts based on facts, circumstances and judgments regarding each receivable. Customer payment history and patterns, length of relationship with the customer, historical losses, economic and political conditions, trends and individual circumstances are among the items considered when evaluating the collectability of the receivables. Accounts are reviewed regularly for collectability and those deemed uncollectible are written off. At December 31, 2021 and December 31, 2020, the Company had an allowance for doubtful accounts of $3,000 and $22,000, respectively.
[3] Inventory: Inventory is stated at the lower of cost or net realizable value. Work in process and finished goods are comprised of labor, overhead and raw material costs. Labor and overhead costs are determined on a rolling average cost basis and raw materials are determined on an average cost basis. At December 31, 2021 and December 31, 2020, the Company established an allowance for slow moving and obsolete inventory of $278,000 and $279,000, respectively.
[4] Income taxes: The Company applies Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) ASC 740Income Taxes (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, provided for operating loss carryforwards and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. ASU 2019-12, issued in December 2019 was adopted by the Company on January 1, 2021. ASU 2019-12 reduced the complexity of ASC 740 by removing exemptions and simplifying the accounting for franchise taxes, deferred taxes and taxes related to employee’s stock ownership plan.
[5] Advertising expense: Advertising costs are expensed as incurred.
[6] Leases: The Company applies FASB ASC 842 – Leases (Topic 842) and recognizes a lease “right of use” asset and a lease liability on its balance sheet related to its operating leases, and discloses key information about its leasing arrangements. At December 31, 2021, the Company’s current lease asset was $35,000 and its current lease liability was $35,000. At December 31, 2021, the Company’s long-term lease asset was $5,000 and its long-term lease liability was $3,000.
[7] Depreciation and amortization: Property, plant and equipment are depreciated utilizing the straight-line method over their estimated useful lives; generally 3-5 years for equipment and 30 years for buildings. Leasehold improvements and capitalized lease assets are amortized by the straight-line method over the shorter of their estimated useful lives or the term of the lease. Intangible assets include the cost of patent applications, which are deferred and charged to operations over 19 years. The accumulated amortization of patents is $206,000 at December 31, 2021 and $198,000 at December 31, 2020. At December 31, 2021, the Company determined that its patent asset was impaired and recorded a $100,000 write off of the patent asset. Due to the write-off, no future amortization expense is expected related to the specific patents within the asset.
[8] Revenue recognition: The Company recognizes revenue in accordance with ASC Topic 606.The Company’s revenues result from the sale of goods and reflects the consideration to which the Company expects to be entitled. For its customer contracts, the Company’s performance obligations are identified; which is delivering goods at a determined transaction price, allocation of the contract transaction price with performance obligations (when applicable), and recognition of revenue when (or as) the performance obligation is transferred to the customer. Goods are transferred when the customer obtains control of the goods (which is upon shipment to the customer). The Company’s revenues are recorded at a point in time from the sale of tangible products. Revenues are recognized when products are shipped.
Product returns, discounts and allowances are variable consideration and are recorded as a reduction of revenue in the same period that the related sale is recorded. The Company has reviewed the overall sales transactions for variable consideration and has determined that these costs are not significant. The Company has not experienced any impairment losses, has no future performance obligations and does not capitalize costs to obtain or fulfill contracts.
[9] Shipping and handling: Shipping and handling fees charged to customers are included as a reduction to revenue, and shipping and handling costs incurred by the Company, to the extent of those costs charged to customers, are included in cost of sales.
[10] Research and development: Research and development (“R&D”) costs are charged to operations when incurred. These costs include salaries, benefits, travel expense, costs associated with regulatory applications, supplies, depreciation of R&D equipment and other miscellaneous expenses.
[11] Net loss per common share: Basic loss per common share is calculated by dividing net loss by the weighted average number of outstanding common shares during the period.
Potential common shares outstanding as of December 31, 2021 and 2020:
| | December 31, 2021 | | | December 31, 2020 | |
Options | | | 1,937,000 | | | | 1,987,000 | |
Total | | | 1,937,000 | | | | 1,987,000 | |
For Fiscal 2021 and Fiscal 2020, the number of securities not included in the diluted loss per share was 1,937,000 and 1,987,000, respectively, as their effect was anti-dilutive due to a net loss in each year.
[12] Use of estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our management believes the major estimates and assumptions impacting our financial statements are the following:
| · | Estimates of the fair value of stock options and warrants at date of grant; |
| | |
| · | Allowance for doubtful accounts; |
| | |
| · | Allowance for slow moving and obsolete inventory; |
| | |
| · | Estimates of accruals and liabilities; and |
| | |
| · | Deferred income tax valuation allowance. |
Estimates are determined using available information. Considerable judgment is required to interpret the specific data used to develop the estimates. The use of different assumptions and/or different valuation techniques may have a material effect on the value of our assets, liabilities and taxes.
The fair value of stock options issued to employees, members of our Board of Directors, and consultants and of warrants issued in connection with debt financings is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment.
As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding.
If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the equity-based compensation expense could be significantly different from what we have recorded in the current period.
Actual results may differ from estimates and assumptions of future events.
[13] Impairment of long-lived and intangible (patent) assets: When the carrying balance of the Company’s patents is more than what it could be sold for on the open market and/or is not recoverable through future use, the Company decreases its value. In determining whether the carrying value is not recoverable, the Company estimates the sum of the undiscounted expected cash flows from the use of the patent or its possible sale. If the results in an amount less that the patents’ value on the financial statements, the Company will deem the patent’s carrying value on the balance sheet to be impaired by the amount that the carrying value exceeds the fair market value of the asset. The decrease in the patent’s value will then be included as a loss in the Company’s profit and loss statement. Because it is difficult to determine and support what our patents could be sold for on the open market, we performed an expected cash flow analysis to determine impairment. Due to the nature of the patents included in the Company’s patent asset and expected revenue specifically related to the patents known at the time of the analysis, the Company determined the patent asset was impaired at December 31, 2021 and recorded a loss of $100,000 in its statement of operations for Fiscal 2021. The Company did not record any loss related to patent impairment in Fiscal 2020. The Company believes the carrying values of its fixed assets are recoverable and impairment does not exist.
[14] Financial Instruments: The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short and long-term debt. The fair values of these financial instruments approximate their stated amounts because of the short maturity of the instruments.
The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy under ASC 820 are described below:
Level 1: Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
Level 3: Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities
The Company endeavors to utilize the best available information in measuring fair value. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:
Cash —The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value due to the short-term maturity of these instruments.
Line of Credit and short term and long-term debt—The carrying amounts of the Company’s borrowings under its line of credit and other long-term debt approximates fair value, based upon current interest rates, some of which are variable interest rates.
Other Asset/liabilities– The carrying amounts reported in the balance sheet for other current assets and liabilities approximates their fair value, based on the nature of the assets and liabilities.
[15] Accounting for share-based payments and stock warrants: The Company accounts for stock-based compensation in accordance with ASC No. 718, “Compensation-Stock Compensation.” ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options and warrants and recognizes compensation expenses starting on the date of the grant and over the vesting period of the stock option/warrant. There were 1,937,000 stock options issued and outstanding as of December 31, 2021, all of which are completely vested.
[16] Concentration of credit risk: The Company sells products primarily to United States customers and distributors. Credit is extended based on an evaluation of the customer’s financial condition.
At December 31, 2021, one customer accounted for 64.5%, one customer accounted for 12.7% and one customer accounted for 10.4% of accounts receivable. A substantial portion of these balances was collected in the first quarter of the year ending December 31, 2022.
At December 31, 2020, one customer accounted for 68.0% of the Company’s accounts receivable. A substantial portion of this balance was collected in the first quarter of the year ending December 31, 2021. Due to the long standing nature of the Company’s relationship with this customer and contractual obligations, the Company is confident it will recover these amounts.
The Company has established an allowance for doubtful accounts of $3,000 and $22,000 December 31, 2021 and December 31, 2020, respectively, based on factors surrounding the credit risk of our customers and other information.
The Company maintains certain cash balances at financial institutions that are federally insured and at times the balances have exceeded federally insured limits.
[17] New accounting pronouncements:
In the year ended December 31, 2021, we adopted the following accounting standards set forth by the Financial Accounting Standards Board (“FASB”):
ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”, issued in December 2019 reduces the complexity by removing exemptions and simplifying the accounting for franchise taxes, deferred taxes and taxes related to employee’s stock ownership plan. The requirements in ASU 2019-12 were effective for public companies for fiscal years beginning after December 15, 2020, including interim periods. The Company adopted ASU 2019-02 on January 1, 2021 and the adoption did not have an impact on the Company’s financial condition or results of operation.
ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)”, issued in January 2020, clarifies certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improved current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The requirements in ASU 2021-01 were effective for public companies for fiscal years beginning after December 15, 2020, including interim periods within the fiscal year. The Company adopted ASU 2020-01 on January 1, 2021 and the adoption did not have an impact on the Company’s financial condition or results of operation.
ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, issued in August 2020 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments also simplify the guidance in ASC Subtopic 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The amendments were effective for public companies for fiscal years beginning after December 15, 2021. Early adoption was permitted, but no earlier than fiscal years beginning after December 15, 2020. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company adopted ASU 2020-06 on January 1, 2021 and the adoption did not have an impact on the Company’s financial condition or results of operation.
ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), issued in May 2021, addresses an issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2021-04 on January 1, 2022 and the adoption did not have an impact on the Company’s financial condition or results of operations.
ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, issued in November 2021 requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The Company adopted ASU 2021-10 on January 1, 2022 and the adoption did not have an impact on our financial condition or results of operations as ASU-2021-10 only impacts annual financial statement footnote disclosures.
Accounting Standards Issued; Not Yet Adopted
Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.
NOTE B - INVENTORY
Inventory is comprised of the following:
| | December 31, 2021 | | | December 31, 2020 | |
Raw materials | | $ | 462,000 | | | $ | 534,000 | |
Work in process | | | 109,000 | | | | 127,000 | |
Finished goods | | | 150,000 | | | | 154,000 | |
Allowance for slow moving and obsolete inventory | | | (278,000 | ) | | | (279,000 | ) |
| | $ | 443,000 | ) | | $ | 536,000 | |
NOTE C – PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment, is comprised of the following:
| | December 31, 2021 | | | December 31, 2020 | |
| | | | | | |
Land | | $ | 102,000 | | | $ | 102,000 | |
Buildings and improvements | | | 1,352,000 | | | | 1,352,000 | |
Manufacturing and warehouse equipment | | | 2,110,000 | | | | 2,110,000 | |
Office equipment (incl. furniture and fixtures) | | | 412,000 | | | | 412,000 | |
| | | 3,976,000 | | | | 3,976,000 | |
Less accumulated depreciation | | | (3,459,000 | ) | | | (3,400,000 | ) |
| | $ | 517,000 | | | $ | 576,000 | |
Depreciation expense was $60,000 in Fiscal 2021 and $71,000 in Fiscal 2020.
NOTE D – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following as of December 31, 2021 and December 31, 2020:
| | December 31, 2021 | | | December 31, 2020 | |
Accounting fees | | $ | 70,000 | | | $ | 80,000 | |
Interest payable | | | 25,000 | | | | 22,000 | |
Accounts receivable credit balances | | | 18,000 | | | | 5,000 | |
Sales tax payable | | | 185,000 | | | | 164,000 | |
Deferred compensation | | | 79,000 | | | | 138,000 | |
Customer deposits | | | 52,000 | | | | 167,000 | |
Other current liabilities | | | 38,000 | | | | 44,000 | |
| | $ | 467,000 | | | $ | 620,000 | |
NOTE E – DEBT AND LINE OF CREDIT
The Company’s Line of Credit and Debt consisted of the following as of December 31, 2021 and December 31, 2020:
| | December 31, 2021 | | | December 31, 2020 | |
Loan and Security Agreement with Cherokee Financial, LLC: 5 year note executed on February 15, 2015, at a fixed annual interest rate of 8% plus a 1% annual oversight fee, interest only and oversight fee paid Loan was extended for one year (until February 15, 2021) on February 15, 2020 under the same terms and conditions as original loan. Loan was further extended in February 2021 to February 15, 2022. A penalty of $100,000 was added to the loan principal and the annual interest rate was increased to 10% on February 15, 2021 in connection with the extension. Loan is collateralized by a first security interest in building, land and property. See Note L – Subsequent Events | | $ | 1,000,000 | | | $ | 900,000 | |
Crestmark Line of Credit: Line of credit that will auto-renew on June 22, 2022 for another 12 months unless the Company provides 60 days advance notice of non-renewal. Interest is payable at a variable rate based on WSJ Prime plus 3% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 2% if terminated prior to natural expiration. Loan is collateralized by first security interest in receivables and inventory and the all-in interest rate as of the date of this report is 11.95%. | | | 178,000 | | | | 277,000 | |
2019 Term Loan with Cherokee Financial, LLC: 1 year note at an annual fixed interest rate of 18% paid quarterly in arrears and a balloon payment being due on February 15, 2020. Loan was extended in February 2020, until February 15, 2021, under the same terms and conditions. A penalty of $20,000 was added to the loan principal on February 15, 2020 in connection with the extension of the loan. Loan was further extended in February 2021 to February 15, 2022. Another penalty of $20,000 was added to the loan principal on February 15, 2021 in connection with the additional extension of the loan. See Note L – Subsequent Events | | | 240,000 | | | | 220,000 | |
April 2020 PPP Loan with Crestmark: 2 year SBA loan at 1% interest with first payment due October 2020. Entire Loan principal and all interest were forgiven on August 3, 2021. | | | 0 | | | | 332,000 | |
November 2020 Shareholder Note; no terms, note was paid on February 24, 2021 with proceeds from Lincoln Park financing. | | | 0 | | | | 25,000 | |
November 2020 Shareholder Note: Term loan at 7% interest (Prime + 3.75%), with an initial term of 6 months which was extended for another 6 months on May 4, 2021 to November 4, 2021. Interest only payments are being made on the loan. Loan was extended on November 3, 2021 to November 4, 2022 with no changes to any terms of the note. | | | 50,000 | | | | 50,000 | |
December 2021 Shareholder Notes: Two term loans with two non-affiliated shareholders at 7% interest until principal and interest are both due in full, or until June 15, 2022. The first interest payments are due on March 15, 2022 and payment of final interest and principal are due June 15, 2022, or earlier as we receive further ERC refunds. | | | 75,000 | | | | 0 | |
Total Debt | | $ | 1,543,000 | | | $ | 1,804,000 | |
Current portion | | $ | 1,543,000 | | | $ | 684,000 | |
Long-term portion, net of current portion | | $ | 0 | | | $ | 1,120,000 | |
LOAN AND SECURITY AGREEMENT WITH CHEROKEE FINANCIAL, LLC. (“CHEROKEE”)
On March 26, 2015, the Company entered into a LSA with Cherokee (the “Cherokee LSA”). The debt with Cherokee is collateralized by a first security interest in real estate and machinery and equipment. Under the Cherokee LSA, the Company was provided the sum of $1,200,000 in the form of a 5-year Note at a fixed annual interest rate of 8%; paid quarterly in arrears. In addition to the 8% interest, the Company is required to pay Cherokee a 1% annual fee for oversight and administration of the loan. This oversight fee is paid in cash and is paid contemporaneously with the quarterly interest payments. The Company received net proceeds of $80,000 after $1,015,000 of debt payments, and $105,000 in other expenses and fees which, were deducted from the balance on the Cherokee LSA and amortized over the initial term of the debt (in accordance with ASU No. 2015-03). The Company was required to make annual principal reduction payments of $75,000 on each anniversary of the date of the closing; with the first principal reduction payment being made on February 15, 2016 and the last principal reduction payment being made on February 15, 2019; partially with proceeds received from a term loan with Cherokee (See 2019 Term Loan with Cherokee within this Note E).
In February 2020, the Company extended the due date of the Cherokee LSA (with a balance of $900,000) to February 15, 2021. No terms of the facility were changed in February 2020. In connection with this extension, the Company was required to issue 2% of the $900,000 principal, or $18,000, in 257,143 restricted shares of the Company’s common stock to Cherokee.
On February 24, 2021, the Company completed a transaction related to another one-year Extension Agreement dated February 14, 2021 (the “Second Extension”) with Cherokee under which Cherokee extended the due date of the Cherokee LSA to February 15, 2022.
Under the terms of the Second Extension, the Cherokee LSA was increased to $1,000,000 to include a $100,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. Under the Second Extension, the annual interest rate on the Cherokee LSA was increased to a fixed rate of 10% (the prior fixed rate was 8%) plus a 1% annual oversight fee (that remained unchanged). Interest and the oversight fee are being paid quarterly with the first payment being made on May 15, 2021.
Under the terms of the Second Extension Agreement, if the Company doesn’t pay off the principal on or before February 15, 2022, Cherokee may impose an 8% delinquent fee. This delinquent fee would only apply to the principal balance is on February 15, 2022.
Cantone Research, Inc. earned a 3% fee on the extended principal of $900,000 (or $27,000) for their services related to securing the Second Extension with Cherokee investors. This 3% service fee would be “rebated” if the Company prepaid any, or a portion, of the loan. As an example, if the Company made a principal reduction payment of $100,000, only $97,000 in cash would need to be remitted to Cherokee to have the $100,000 taken off the principal balance. The fee paid to Cantone Research, Inc. was recorded as a bank fee and is included in general and administrative expenses. The Company also paid Cherokee’s legal fees in the amount of $1,000.
The Company recognized $98,000 in interest expense related to the Cherokee LSA in Fiscal 2021 and, $89,000 in interest expense related to the Cherokee LSA in Fiscal 2020 (of which $16,000 is debt issuance cost amortization recorded as interest expense).
On August 18, 2021, we issued 625,000 restricted shares of common stock to Cherokee in lieu of paying the $25,000 August 2021 interest payment in cash. The closing price of the Company’s common shares on the date of the payment in lieu of cash was $0.04.
The Company incurred $8,000 in accrued interest expense at December 31, 2021 related to the Cherokee LSA and, $12,000 in accrued interest expense at December 31, 2020.
As of December 31, 2021 and December 31, 2020, the balance on the Cherokee LSA was $1,000,000 and 900,000, respectively.
In the event of default, this includes, but is not limited to; the Company’s inability to make any payments due under the Cherokee LSA (as amended) Cherokee has the right to increase the interest rate on the financing to 18%. A final balloon payment was due on February 15, 2022. See Note L – Subsequent Events for more information on the status of the Cherokee LSA.
LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”)
On June 29, 2015 (the “Closing Date”), the Company entered into a Loan and Security Agreement (“LSA”) with Crestmark related to a revolving line of credit (the “Crestmark LOC”). The Crestmark LOC is used for working capital and general corporate purposes. Upon completion of the initial 5 year term, the Crestmark LOC automatically renews for additional one (1) year terms unless notice of termination from the Company is received by Crestmark not less than sixty (60) days prior to the end of the renewal term. The current maturity date of the Crestmark LOC is June 22, 2022.
Originally, availability under the Crestmark LOC was based on certain inventory components (under a specific formula previously defined in prior periodic reports) and receivables. The maximum available under the Crestmark LOC was $1,500,000. However on June 25, 2018, the facility was amended to decrease the amounts available under the inventory component until availability under the inventory component was zero; making the Crestmark LOC a receivables-based only line of credit as of July 1, 2020. The facility was further amended on June 22, 2020 to decrease the maximum availability (“Maximum Amount”) under the Crestmark LOC to $1,000,000.
The Crestmark LOC has a minimum loan balance requirement of $500,000. At December 31, 2021, the Company did not meet the minimum loan balance requirement as our balance was $178,000. Under the LSA, Crestmark has the right to calculate interest on the minimum balance requirement rather than the actual balance on the Crestmark LOC (and they are exercising that right). The Crestmark LOC is secured by a first security interest in the Company’s inventory, and receivables and security interest in all other assets of the Company (in accordance with permitted prior encumbrances).
As part of the amendment on June 22, 2020, the minimum Tangible Net Worth (“TNW”) covenant (previously defined in other periodic reports) was removed effective with the quarter ended June 30, 2020.
In the event of a default of the LSA, which includes but is not limited to, failure of the Company to make any payment when due, Crestmark is permitted to charge an Extra Rate. The Extra Rate is the Company’s then current interest rate plus 12.75% per annum.
Interest on the Crestmark LOC is at a variable rate based on the Prime Rate plus 3% with a floor of 5.25%. As of December 31, 2021 and as of the date of this report, the interest only rate on the Crestmark LOC is 6.50%. As of the date of this report, with all fees considered (the interest rate + an Annual Loan Fee of $7,500 + a monthly maintenance fee of 0.30% of the actual average monthly balance from the prior month), the interest rate on the Crestmark LOC is 11.95%.
The Company incurred $50,000 and $41,000 in interest expense related to the Crestmark LOC in Fiscal 2021 and Fiscal 2020, respectively.
Given the nature of the administration of the Crestmark LOC, at December 31, 2021 and December 31, 2020, the Company had $0 in accrued interest.
As of December 31, 2021 and December 31, 2020, the balance on the Crestmark LOC was $178,000 and $277,000, respectively. There is no in additional availability under the Crestmark LOC at December 31, 2021 because we draw any balance available on a daily basis.
2019 TERM LOAN WITH CHEROKEE
On February 25, 2019, the Company entered into an agreement dated (and effective) February 13, 2019 with Cherokee under which Cherokee provided the Company with a loan in the amount of $200,000. The annual interest rate under the 2019 Cherokee Term Loan is 18% (fixed) paid quarterly in arrears.
On February 24, 2020, the Company completed a transaction related to a one-year Extension Agreement dated February 14, 2020 (the “Extension Agreement”) with Cherokee under which Cherokee extended the due date of the 2019 Cherokee Term Loan to February 15, 2021. No terms of the facility were changed under the Extension Agreement. For consideration of the Extension Agreement, the Company issued 1.5% of the $200,000 principal, or $3,000, in 42,857 restricted shares of the Company’s common stock to Cherokee. The Company also incurred a penalty in the amount of $20,000 which was added to the principal balance of the 2019 Cherokee Term Loan.
The final balloon payment was due on February 15, 2021; however the Company further extended the 2019 Cherokee Term Loan on February 24, 2021 to February 15, 2022. Under the terms of the extension, the 2019 Cherokee Term Loan was increased to $240,000 to include a $20,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. The annual interest rate under the 2019 Cherokee Term Loan remains fixed at 18% paid quarterly in arrears with the first interest payment being due on May 15, 2021. If the Company doesn’t pay off the principal on or before February 15, 2022, Cherokee may impose an 8% delinquent fee. This delinquent fee would only apply to the principal balance is on February 15, 2022.
The Company recognized $43,000 in interest expense related to the 2019 Cherokee Term Loan in Fiscal 2021. The Company recognized $40,000 in interest expense related to the 2019 Cherokee Term Loan in Fiscal 2020 (of which $1,000 is debt issuance cost amortization recorded as interest expense).
On August 18, 2021, we issued 270,000 restricted shares of common stock to Cherokee in lieu of paying the $11,000 August 2021 interest payment in cash. The closing price of the Company’s common shares on the date of the payment in lieu of cash was $0.04.
The Company had $4,000 in accrued interest expense related to the 2019 Cherokee Term Loan at December 31, 2021 and $7,000 in accrued interest expense at December 31, 2020. The balance on the 2019 Cherokee Term Loan is $240,000 at December 31, 2021 and $220,000 at December 31, 2020.
In the event of default, this includes, but is not limited to, the Company’s inability to make any payments due under the Agreement; Cherokee has the right to increase the interest rate on the financing to 20%. A final balloon payment was due on February 15, 2022. See Note L – Subsequent Events for more information on the status of the 2019 Cherokee Term Loan.
SBA PAYCHECK PROTECTION LOAN (PPP LOAN)
On April 22, 2020, the Company entered into a Promissory Note (“PPP Note”) for $332,000 with Crestmark Bank, pursuant to the U.S. Small Business Administration Paycheck Protection Program under Title I of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act passed by Congress and signed into law on March 27, 2020. The PPP Note was unsecured, with an interest rate of 1.00% per annum, with principal and interest payments deferred for the first six months, and would mature in two years. On June 15, 2021, the Company applied for forgiveness of the PPP loan in the amount of $332,000 under PPP guidelines. Our forgiveness application was reviewed by the SBA and on August 3, 2021, the Small Business Administration remitted payment to Crestmark Bank for the balance of the PPP Loan principal and all interest due on the PPP Loan.
Interest in the amount of $3,000 was forgiven along with the principal. Since the loan was paid in full, there was $0 in accrued interest at December 31, 2021. The Company had $2,000 in accrued interest expense related to the PPP loan in Fiscal 2020; however as indicated previously, all interest was forgiven in August 2021.
The balance on the PPP Loan was $0 at December 31, 2021 and $332,000 at December 31, 2020.
NOVEMBER 2020 LOAN
On November 6, 2020, the Company entered into a loan agreement with our (then) Chairman of the Board Chaim Davis, under which Davis provided the Company the sum of $25,000 (the “November 2020 Loan”). There were no expenses or interest related to the November 2020 loan. The Company incurred $0 in interest expense in both Fiscal 2021 and Fiscal 2020. The balance on the November 2020 Term Loan was $0 at December 31, 2021 as the principal amount of $25,000 was paid in full on February 24, 2021.
NOVEMBER 2020 SHAREHOLDER TERM LOAN
On November 4, 2020, the Company entered into a loan agreement with an unaffiliated, individual shareholder in the amount of $50,000. There were no expenses related to the term loan and the interest rate is 7% (Prime + 3.75%). The first interest only payment was paid on February 4, 2021 and the final interest payment and 50,000 principal was due on May 4, 2021. On May 4, 2021, the Company extended this loan for another 6 months, or until November 4, 2021. The interest rate and all other terms of the note remained unchanged under the Extension.
On November 4, 2021, the Company entered into a twelve-month Extension Agreement (the “Extension”) with the shareholder. Under the Extension, the principal is now due on November 4, 2022. The interest rate and all other terms of the note remain unchanged under the Extension. All interest payments due to the shareholder have been paid as required with the next interest payment being due on May 4, 2022.
The Company recognized $3,000 in interest expense related to this loan in Fiscal 2021 and less than $1,000 in interest expense in Fiscal 2020. The Company had accrued less than $1,000 in interest expense related to this loan at December 31, 2021 and less than $1,000 at December 31, 2020.
DECEMBER 2021 SHAREHOLDER LOANS
On December 14, 2021, the Company entered into Loan Agreements with two non-affiliated investors resulting in gross (and net) proceeds of $75,000 as there were no costs associated with the loans. The loans bear interest of 7% per annum until principal and interest are both due in full, or until June 15, 2022. The first interest payments are due on March 15, 2022 and payment of final interest and principal are due June 15, 2022, or earlier as we receive further ERC refunds.
OTHER DEBT INFORMATION
In addition to the debt indicated previously, previous debt facilities (paid in full via refinance or conversion into equity) are as follows:
JULY 2019 TERM LOAN WITH CHAIM DAVIS, ET AL
On July 31, 2019, the Company entered into loan agreements with two (2) individuals, under which each individual provided the Company the sum of $7,000 (for a total of $14,000) to be used in connection with certain fees and/or expenses related legal matters of the Company (the “July 2019 Term Loan”). One of the individuals was our (then) Chairman of the Board, Chaim Davis. There were no expenses related to the July 2019 Term Loan. The first payment of principal and interest was due on September 1, 2019 and the last payment of principal and interest was due on October 1, 2020. The annual interest rate of the July 2019 Term Loan was fixed at 7.5% (which represented the WSJ Prime Rate when the loan agreements were executed) +2.0%.
The balance on the 2019 Term Loan was $10,000 at December 31, 2019. In February 2020, all amounts loaned under the July 2019 Term Loan were converted into equity as part of the February 2020 Private Placement. Any interest that was incurred under the facility in 2019 and up to the conversion in February 2020 was forgiven by the holders. The balance on the July 2019 Term Loan was $0 at December 31, 2020.
DECEMBER 2019 CONVERTIBLE NOTE
On December 31, 2019, the Company entered into a Convertible Note with one individual in the amount of $25,000 (“2019 Convertible Note”). Under the terms of the 2019 Convertible Note, the principal amount would convert into equity within 120 days of the origination of the note or upon the close of a contemplated private placement in early 2020, whichever was sooner. The 2019 Convertible Note did not bear any interest and was ultimately converted into equity as part of a private placement closed in February 2020. The balance on the 2019 Convertible Note was $0 at December 31, 2020.
NOTE F – INCOME TAXES
The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits Net Operating Loss (“NOL”) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. With regards to the use of net losses incurred for 2018 and later, such net operating losses have no expiration, while taxable income can only be offset up to 80% of taxable income. Net operating losses incurred prior to 2018 may be fully utilized to offset taxable income.
A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows:
| | Year Ended December 31, 2021 | | | Year Ended December 31, 2020 | |
Tax expense at federal statutory rate | | (21 | %) | | (21 | %) |
State tax expense, net of federal tax effect | | | 0 | % | | | 0 | % |
Permanent differences | | (12 | %) | | | - | |
Expired NOL | | | 119 | % | | | 42 | % |
Deferred income tax asset valuation allowance | | (86 | %) | | (21 | %) |
Effective income tax rate | | (0 | %) | | (0 | %) |
Significant components of the Company’s deferred income tax assets are as follows:
| | December 31, 2021 | | | December 31, 2020 | |
| | | | | | |
Inventory capitalization | | $ | 8,000 | | | $ | 8,000 | |
Inventory allowance | | | 72,000 | | | | 73,000 | |
Allowance for doubtful accounts | | | 1,000 | | | | 6,000 | |
Accrued compensation | | | 18,000 | | | | 18,000 | |
Stock based compensation | | | 160,000 | | | | 162,000 | |
Deferred wages payable | | | 21,000 | | | | 36,000 | |
Depreciation – property, plant and equipment | | | (24,000 | ) | | | (5,000 | ) |
Research and development credits | | | 24,000 | | | | 22,000 | |
Net operating loss carry-forward | | | 2,631,000 | | | | 3,123,000 | |
Total gross deferred income tax assets | | | 2,911,000 | | | | 3,443,000 | |
Less deferred income tax assets valuation allowance | | | (2,911,000 | ) | | | (3,443,000 | ) |
Net deferred income tax assets | | $ | 0 | | | $ | 0 | |
The valuation allowance for net deferred income tax assets as of December 31, 2021 and December 31, 2020 was $2,911,000 and $3,443,000, respectively. The net change in the valuation allowance was $532,000 for Fiscal 2021 and $224,000 for Fiscal 2020. The Company believes that it is more likely than not that the net deferred tax assets will not be realized.
As of December 31, 2021, the prior three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes.
At December 31, 2021, the Company had Federal net operating loss carry-forwards for income tax purposes of approximately $2,631,000 and research and development credits of $24,000. The Company’s net operating loss carry-forwards begin to expire in 2022 and continue to expire through 2037. Net operating losses incurred from 2018 to date have no expiration date. In assessing the realizability of net deferred income tax assets, management considers whether or not it is more likely than not that some portion or all of the net deferred income tax assets will be realized. The ultimate realization of net deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment.
The Company’s ability to utilize the operating loss carry-forwards may be subject to an annual limitation in future periods pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, if future changes in ownership occur.
The Company recognizes potential interest and penalties related to income tax positions as a component of the provision for income taxes on operations. The Company does not anticipate that total unrecognized tax benefits will materially change in the next twelve months.
NOTE G – OTHER INCOME / EXPENSE
Other income of $718,000 in Fiscal 2021 consisted of income related to the forgiveness of our PPP loan in the amount of $335,000, other income of $58,000; which is $50,000 related to certain non-refundable prepayments (customer deposits) that were forfeited when the customer did not remit the remaining amounts due on the order and $8,000 in income related to gains on certain liabilities, $619,000 in income from the Employee Retention Credit recognized in Fiscal 2021 (which is $44,000 in credits taken in Q3 2021, $38,000 in credit taken in Q4 2021 and $537,000 in refunds filed for credits in the first three quarters of 2021). This income was offset by interest expense associated with our credit facilities (our line of credit, our two loans with Cherokee Financial, LLC and a shareholder loan) and a $100,000 write off related to impairment of the Company’s patent asset.
Other expense of $173,000 in Fiscal 2020 consisted of interest expense associated with our credit facilities (our line of credit, equipment loan with Crestmark Bank and our two loans with Cherokee Financial, LLC) nominally offset by $2,000 in other income.
NOTE H – STOCKHOLDERS’ EQUITY
[1] Stock option plans: The Company currently has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by our Board of Directors and approved by our shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares.
[2] Stock options: During Fiscal 2021 and Fiscal 2020, the Company issued 0 options to purchase shares of common stock.
As of December 31, 2021, there were 1,937,000 options issued and outstanding under the 2001 Plan. There were no options issued under the 2013 Plan, making the total issued and outstanding options 1,937,000 as of December 31, 2021. Of the total options issued and outstanding, 1,937,000 were fully vested as of December 31, 2021. As of December 31, 2021, there were 1,780,000 options available for issuance under the 2001 Plan and 4,000,000 options available under the 2013 Plan.
Stock option activity for Fiscal 2021 and Fiscal 2020 is summarized as follows: (the figures contained within the tables below have been rounded to the nearest thousand)
| | Year Ended December 31,2021 | | | Year Ended December 31, 2020 | |
| | Shares | | | Weighted Average Exercise Price | | | Aggregate Intrinsic Value | | | Shares | | | Weighted Average Exercise Price | | | Aggregate Intrinsic Value | |
Options outstanding-beginning of year | | | 1,987,000 | | | $ | 0.13 | | | | | | | 2,252,000 | | | $ | 0.13 | | | | |
Granted | | | 0 | | | NA | | | | | | | 0 | | | NA | | | | |
Exercised | | | 0 | | | NA | | | | | | | 0 | | | NA | | | | |
Cancelled/expired | | | (50,000 | ) | | $ | 0.13 | | | | | | | (265,000 | ) | | $ | 0.10 | | | | |
Options outstanding-end of year | | | 1,937,000 | | | $ | 0.13 | | | $ | 1,000 | | | | 1,987,000 | | | $ | 0.13 | | | $ | 291,324 | |
Options exercisable-end of year | | | 1,937,000 | | | $ | 0.13 | | | | | | | | 1,987,000 | | | $ | 0.13 | | | | | |
The following table presents information relating to stock options outstanding as of December 31, 2021:
| | Options Outstanding | | | Options Exercisable | |
| | | | | Weighted | | | Weighted | | | | | | Weighted | |
| | | | | Average | | | Average | | | | | | Average | |
Range of Exercise | | | | | Exercise | | | Remaining | | | | | | Exercise | |
Price | | Shares | | | Price | | | Life in Years | | | Shares | | | Price | |
| | | | | | | | | | | | | | | |
$0.07 - $0.11 | | | 910,000 | | | $ | 0.11 | | | | 4.59 | | | | 910,000 | | | $ | 0.11 | |
$0.12 - $0.16 | | | 730,000 | | | $ | 0.13 | | | | 2.90 | | | | 730,000 | | | $ | 0.13 | |
$0.18 - $0.26 | | | 297,000 | | | $ | 0.19 | | | | 0.68 | | | | 297,000 | | | $ | 0.19 | |
TOTAL | | | 1,937,000 | | | $ | 0.13 | | | | 3.35 | | | | 1,937,000 | | | $ | 0.13 | |
The Company recognized $0 in share based payment expense related to stock options in Fiscal 2021 and $2,000 in share based payment expense in Fiscal 2020. As of December 31, 2021, there was $0 of total unrecognized share based payment expense related to stock options.
[3] Warrants:
Warrant activity for Fiscal 2021 and Fiscal 2020 is summarized as follows:
| | Year Ended December 31, 2021 | | Year Ended December 31, 2020 | |
| | Shares | | | Weighted Average Exercise Price | | Aggregate Intrinsic Value | | Shares | | | Weighted Average Exercise Price | | | Aggregate Intrinsic Value | |
Warrants outstanding at beginning of year | | | 0 | | | NA | | | | | 2,000,000 | | | $ | 0.18 | | | | |
Granted | | | 0 | | | NA | | | | | 0 | | | NA | | | | |
Exercised | | | 0 | | | NA | | | | | 0 | | | NA | | | | |
Cancelled/expired | | | 0 | | | NA | | | | | (2,000,000 | ) | | NA | | | | |
Warrants outstanding at end of year | | | 0 | | | NA | | None | | | 0 | | | NA | | | None | |
Warrants exercisable at end of year | | | 0 | | | NA | | | | | 0 | | | NA | | | | |
NOTE I – COMMITMENTS, CONTINGENCIES AND OTHER MATTERS
[1] Operating leases: The Company leases office and R&D/production facilities in New Jersey under a, non-cancellable operating lease through December 31, 2022. The Company also leases office support equipment through July 2022 and December 2025. At December 31, 2021, the future minimum rental payments under these operating leases are as follows:
2022 | | | 38,000 | |
2023 | | | 1,000 | |
2024 | | | 1,000 | |
2025 | | | 1,000 | |
2026 | | | 0 | |
| | $ | 41,000 | |
Rent Expense was $47,000 in Fiscal 2021 and $46,000 in Fiscal 2020.
[2] Employment agreements: The Company has an employment agreement in place with its Chief Executive Officer/Principal Financial Officer, Melissa Waterhouse. The employment agreement with Ms. Waterhouse provides for a $160,000 annual salary (although the salary of Ms. Waterhouse was deferred by 10% through June 2020; resulting in deferred compensation due to Waterhouse in the amount of $73,000 through December 31, 2021). The employment agreement contains severance provisions; in the event the Company terminates Ms. Waterhouse’s employment for any reason other than cause (which is defined under the employment agreement), Ms. Waterhouse would receive severance pay equal to 12 months of her base salary at the time of termination, with continuation of all medical benefits during the twelve-month period at the Company’s expense. In addition, Ms. Waterhouse may tender her resignation and elect to exercise the severance provision if she is required to relocate more than 50 miles from the Company’s New York facility as a continued condition of employment, if there is a substantial change in the responsibilities normally assumed by her position, or if she is asked to commit or conceal an illegal act by an officer or member of the board of directors of the Company. In the case of a change in control of the Company, Ms. Waterhouse would be entitled to severance pay equal to two times her base salary under certain circumstances.
[3] Legal:
From time to time, the Company may be named in immaterial legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such litigation cannot be predicted, if the Company is unsuccessful in defending any such immaterial litigation, the resulting financial losses are not expected to have a material adverse effect on the financial position, results of operations and cash flows of our company.
[4] Property Taxes: The Company is currently delinquent in its property and school taxes. The Company has been communicating with the county over the past several months to discuss options for payment of the delinquent taxes; including, but not limited to, entering into a payment plan offered by the county.
NOTE J – LINCOLN PARK EQUITY LINE OF CREDIT
On December 9, 2020, the Company entered into a Purchase Agreement and a Registration Rights Agreement with Lincoln Park (together the “Agreements”) under which Lincoln Park agreed to purchase from the Company, from time to time, up to $10,250,000 of its shares of common stock, par value $0.01 per share, subject to certain limitations set forth in the Purchase Agreement, during the term of the Purchase Agreement (two years). On December 9, 2020, the Company sold 500,000 shares of common stock to Lincoln Park in an initial purchase under the Purchase Agreement for a purchase price of $125,000. As consideration for Lincoln Park’s irrevocable commitment to purchase common shares upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, on December 9, 2020, the Company also issued 1,250,000 shares of common stock to Lincoln Park as commitment shares. The commitment shares were valued at $138,000 and recorded as an addition to equity for the issuance of common stock and treated as a reduction to equity as a cost of capital to be raised under the Lincoln Park facility. While this commitment fee relates to the entire offering and the purchases of common shares that will occur over time, the Company recorded the entire commitment fee as issuance costs in additional paid-in capital at the time the commitment fee was paid because the offering had been consummated, but, at the time the shares of common stock were issued for the commitment fee, there was no guaranteed future economic benefit from the payment of the fee.
Pursuant to the terms of the Registration Rights Agreement, the Company was required to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 (the “Registration Statement”) to register for resale under the Securities Act of 1933, as amended (the “Securities Act”), the shares of common stock issued and sold as well as the shares of common stock that the Company may elect in the future to issue and sell to Lincoln Park from time to time under the Purchase Agreement. The Company filed the Form S-1 on December 29, 2020 and the SEC declared the Form S-1, as amended, on January 11, 2022. On January 11, 2021, the Company sold the remaining 500,000 shares of common stock to Lincoln Park required as an initial purchase under the Purchase Agreement for a purchase price of $125,000.
From and after the Commencement, under the Purchase Agreement, on any business day selected by the Company on which the closing sale price of its common stock exceeds $0.05, the Company may direct Lincoln Park to purchase up to 200,000 common shares on the applicable purchase date (a “Regular Purchase”), which maximum number of shares may be increased to certain higher amounts up to a maximum of 250,000 common shares, if the market price of the Company’s common stock at the time of the Regular Purchase equals or exceeds $0.20 and which maximum number of shares may be further increased to certain higher amounts up to a maximum of 500,000 common shares, if the market price of the Company’s common stock at the time of the Regular Purchase equals or exceeds $0.50 (such share and dollar amounts subject to proportionate adjustments for stock splits, recapitalizations and other similar transactions as set forth in the Purchase Agreement), provided that Lincoln Park’s purchase obligation under any single Regular Purchase may not exceed $500,000. The purchase price of the shares of common stock the Company may elect to sell to Lincoln Park under the Purchase Agreement in a Regular Purchase, if any, will be based on 95% of the lower of: (i) the lowest sale price on the purchase date for such Regular Purchase and (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common shares during the 15 consecutive business days ending on the business day immediately preceding the purchase date for a Regular Purchase (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction.) In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts of the Company’s common shares in “accelerated purchases” and in “additional accelerated purchases” under the terms set forth in the Purchase Agreement.
Lincoln Park cannot require the Company to sell them any common stock, but is obligated to make purchases as the Company directs, subject to certain conditions. There are no upper limits on the price per share that Lincoln Park must pay for the Company’s common shares that the Company may elect to sell to them pursuant to the Purchase Agreement. In all instances, the Company may not sell common shares to Lincoln Park under the Purchase Agreement to the extent that the sale of shares would result in Lincoln Park beneficially owning more than 9.99% of our common shares. There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, other than the Company’s agreement not to enter into any “variable rate” transactions (as defined in the Purchase Agreement) with any third party, subject to certain exceptions set forth in the Purchase Agreement, for the period set forth in the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any direct or indirect short selling or hedging of the Company’s common stock.
Actual sales of common stock to Lincoln Park under the Purchase Agreement depends on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Company’s common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds to the Company from sales of common stock to Lincoln Park under the Purchase Agreement depend on the frequency and prices at which the Company sells common stock to Lincoln Park under the Purchase Agreement. Proceeds the Company receives from sales of common stock to Lincoln Park under the Purchase Agreement are being used at the sole discretion of Company management and are being used for general corporate purposes, capital expenditures and working capital.
The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. During any “event of default” under the Purchase Agreement, Lincoln Park does not have the right to terminate the Purchase Agreement; however, the Company may not initiate any Regular Purchase or any other purchase of common shares by Lincoln Park, until such event of default is cured. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. In addition, in the event of bankruptcy proceedings by or against the Company, the Purchase Agreement will automatically terminate. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to limitations agreed upon by the contracting parties.
In Fiscal 2021, the Company sold 6,500,000 shares of common stock that represented the balance of the Initial Purchase and 6,000,000 shares of common stock to Lincoln Park as Regular Purchases. The Company received proceeds of $639,000 from these purchases. In Fiscal 2020, the Company sold 500,000 shares of common stock to Lincoln Park in an initial purchase under the Purchase Agreement for a purchase price of $125,000.
NOTE K –EMPLOYEE RETENTION CREDIT RECEIVABLE
The employee retention credit (“ERC”), as originally enacted on March 27, 2020 by the CARES Act, is a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer pays to employees after March 12, 2020, and before January 1, 2021. The Taxpayer Certainty and Disaster Tax Relief Act (the “Relief Act”), enacted on December 27, 2020, amended, and extended the ERC. On March 1, 2021, the IRS released Notice 2021-20 to provide guidance on the original ERC, as modified by the Relief Act. The Relief Act extended and enhanced the ERC for qualified wages paid after December 31, 2020 through June 30, 2021. Under the Relief Act, eligible employers may claim a refundable tax credit against certain employment taxes equal to 70% of the qualified wages an eligible employer pays to employees after December 31, 2020 through June 30, 2021. Under the American Rescue Plan Act and previously under the Consolidated Appropriations Act, 2021, the ERC was extended and expanded allowing claims through December 31, 2021 by eligible employers who retained employees during the Covid-19 pandemic. However, on November 5, 2021, the House of Representatives passed the Infrastructure Investment and Jobs Act (“Infrastructure Bill”) under which the ERC would terminate as of September 20, 2021 instead of December 31, 2021 and, President Biden signed the bill on November 15, 2021.
The maximum qualified wages for each employee under the current ERC is $10,000 per quarter. Also, because we have 100 or fewer full-time employees, health plan expenses borne by the Company can also be includes as qualified wages in addition to salary. To qualify for the ERC in 2021, an employer must have experienced at least a 20% reduction in gross receipts when compared to the same quarter in either 2020 or 2019. During the first quarter of 2021, the second quarter of 2021 and the third quarter of 2021, the Company qualified for the ERC when comparing its 2021 quarters with both 2020 and 2019 quarters. In August 2021, the Company’s payroll service provider processed and mailed a Form 941-X to claim a refund in the amount of $202,000 on qualified wages paid in the first quarter of 2021. Due to a change in the Form 941-X, the Company’s payroll service provider did not process and mail its Form 941-X to claim a refund in the amount of $198,000 on qualified wages paid in the second quarter of 2021 until October 28, 2021. In the middle of the third quarter of Fiscal 2021, the Company began taking the ERC in its current payroll; which reduced the Company’s payroll by approximately $44,000 in the third quarter of 2021 and $38,000 in the fourth quarter of Fiscal 2021 (until the ERC program was ended as previously indicated). The Company did not have to amend its Form 941 for the third quarter of 2021 so, a Form 941 claiming a refund in the amount of $137,000 was filed electronically with the IRS on November 1, 2021 by the Company’s payroll service provider. Upon passing of the Infrastructure Bill, the Company ceased taking the ERC in its current payroll.
On December 28, 2021, we received our refund for the third quarter of Fiscal 2021 in the amount of $137,000. Shortly before receiving our first refund, we spoke with the Internal Revenue Service (“IRS”) to obtain statuses of our filings. It was then that we were informed that they did not have record of receiving our Form 941-X for the first quarter of Fiscal 2021 (which was mailed by our service provider in August 2021). We re-sent the Form 941-X for the first quarter of Fiscal 2021 via overnight service on December 31, 2021 and the IRS received it on January 5, 2022. This lack of receipt will result in a delay in receiving our expected refund in the amount of $203,000. Based on our discussion with the IRS, we were expecting the refund for the second quarter of Fiscal 2020 sometime in February 2022; however, as of the date of this report, we have not received any further refund payments. The Company’s expected refunds; totaling $400,000, are included on the Condensed Balance Sheets under current assets, as well as on the Company’s Condensed Statements of Operations under other income.
Laws and regulations concerning government programs, including the Employee Retention Credit are complex and subject to varying interpretations. Claims made under the CARES Act may also be subject to retroactive audit and review. There can be no assurance that regulatory authorities will not challenge the Company’s claim to the ERC, and it is not possible to determine the impact (if any) this would have upon the Company. Although the Company has recorded $400,000 under other long term liabilities on our Condensed Balance Sheets at December 31, 2021, even if the Company’s refund claim was challenged and ultimately denied, the Company would not actually have to remit $400,000 to the IRS as that amount has already been remitted to the IRS.
NOTE L – SUBSEQUENT EVENTS
Financial Advisory Agreement
On March 7, 2022, the Company entered into a Financial Advisory Agreement (the “Agreement”) with Landmark Pegasus, Inc. (‘Landmark”). The Agreement provides that Landmark will provide certain financial advisory services for a minimum period of 3 months (which period commenced on February 28, 2022), and as consideration for these services, the Company will pay Landmark (a) a retainer fee consisting of 500,000 restricted shares of common stock and a warrant to purchase 2.75 million shares of the Company’s common stock at a strike price equal to the average closing price of the Company’s common shares for the 30 days preceding the Agreement, or $0.035 per share, resulting in gross proceeds to the Company in the amount of $96,250.00. The warrant will vest upon the closing of a transaction involving Landmark or upon the invocation of a “Breakup Fee”.
The Breakup Fee will be invoked upon the generation of a specific transaction to ABMC which meets certain criteria agreed upon by both the Company and Landmark; which transaction is then rejected by the Company. The Company will also pay to Landmark a “Success Fee” for the consummation of a transaction closing during the term of the Agreement and for 12 months thereafter, between the Company and any party first introduced to the Company by Landmark, or with any party the Company has specifically requested Landmark’s assistance with the transaction.
Upon invocation of the Breakup Fee or payment of the Success Fee, the Company will also issue an additional 250,000 restricted shares of the Company’s common stock.
In the event that the Company consummates a transaction involving the provision of services to any party introduced to the Company by Landmark or with any party the Company has specifically requested Landmark’s assistance with, the Company will pay Landmark 10% of any revenues received from the transaction, unless this percentage is modified by both the Company and Landmark in writing. There is no material relationship between the Company and Landmark, other than with respect to the Agreement.
Cherokee LSA and 2019 Term Loan
As of the date of this report, the Company has not remitted the February 2022 interest and balloon payments required under the Cherokee LSA in the amount of $1,000,000 and the 2019 Cherokee Term Loan in the amount of $240,000. The Company is in discussions with Cherokee related to these payments including, but not limited to, the possible payoff of the two credit facilities via a refinance or further extension of the facilities. Considering these discussions, as of the date of this report, Cherokee has not called a default under either facility nor have they imposed default interest or penalties under either facility. The Company does expect to conclude these discussions with Cherokee shortly after filing this Annual Report on Form 10-K and expects to file a Current Report on Form 8-K when required.
NOTE M- SEGMENT AND GEOGRAPHIC INFORMATION
The Company operates in one reportable segment. All of the Company’s long-lived assets are located within the United States.
Information concerning net sales by principal geographic location is as follows:
| | Year Ended December 31, 2021 | | | Year Ended December 31, 2020 | |
United States | | $ | 2,053,000 | | | $ | 3,417,000 | |
North America (not domestic) | | | 0 | | | | 4,000 | |
Europe | | | 29,000 | | | | 55,000 | |
Asia/Pacific Rim | | | 2,000 | | | | 17,000 | |
South America | | | 134,000 | | | | 616,000 | |
Africa | | | 0 | | | | 38,000 | |
| | $ | 2,218,000 | | | $ | 4,147,000 | |
Historical – Nine Months Ended September 30, 2022
Condensed Balance Sheets
| | September 30, | | | December 31, | |
| | 2022 | | | 2021 | |
ASSETS | | (Unaudited) | | | | |
Current assets | | | | | | |
Cash and cash equivalents | | $ | 10,000 | | | $ | 115,000 | |
Accounts receivable, net of allowance for doubtful accounts of $2,000 at September 30, 2022 and $3,000 at December 31, 2021 | | | 39,000 | | | | 323,000 | |
Inventory, net of allowance of $256,000 at September 30, 2022 and $278,000 at December 31, 2021 | | | 380,000 | | | | 443,000 | |
Employee retention credit receivable | | | 202,000 | | | | 400,000 | |
Prepaid expenses and other current assets | | | 24,000 | | | | 24,000 | |
Right of use asset – operating leases | | | 15,000 | | | | 35,000 | |
Total current assets | | | 670,000 | | | | 1,340,000 | |
Property, plant and equipment, net | | | 479,000 | | | | 517,000 | |
Right of use asset – operating leases | | | 7,000 | | | | 5,000 | |
Other assets | | | 21,000 | | | | 21,000 | |
Total assets | | $ | 1,177,000 | | | $ | 1,883,000 | |
| | | | | | | | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | | | | | | | | |
Current liabilities | | | | | | | | |
Accounts payable | | $ | 950,000 | | | $ | 682,000 | |
Accrued expenses and other current liabilities | | | 544,000 | | | | 467,000 | |
Right of use liability – operating leases | | | 13,000 | | | | 35,000 | |
Wages payable | | | 90,000 | | | | 97,000 | |
Line of credit | | | 0 | | | | 178,000 | |
Current portion of long-term debt | | | 1,595,000 | | | | 1,365,000 | |
Total current liabilities | | | 3,192,000 | | | | 2,824,000 | |
Right of use liability – operating leases | | | 7,000 | | | | 3,000 | |
Total liabilities | | | 3,199,000 | | | | 2,827,000 | |
COMMITMENTS AND CONTINGENCIES | | | | | | | | |
Stockholders' deficit: | | | | | | | | |
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at September 30, 2022 and December 31, 2021 | | | 0 | | | | 0 | |
Common stock; par value $.01 per share; 75,000,000 shares authorized; 48,098,476 issued and outstanding at September 30, 2022 and 47,598,476 issued and outstanding as of December 31, 2021 | | | 481,000 | | | | 476,000 | |
Additional paid-in capital | | | 22,403,000 | | | | 22,393,000 | |
Deficit | | | (24,906,000 | ) | | | (23,813,000 | ) |
Total stockholders’ deficit | | | (2,022,000 | ) | | | (944,000 | ) |
Total liabilities and stockholders’ deficit | | $ | 1,177,000 | | | $ | 1,883,000 | |
|
Historical – Nine Months Ended September 30, 2022 Condensed Statements of Operations |
|
(Unaudited) |
| | For The Nine Months Ended | |
| | September 30, | |
| | 2022 | | | 2021 | |
| | | | | | |
Net sales | | $ | 746,000 | | | $ | 1,709,000 | |
| | | | | | | | |
Cost of goods sold | | | 799,000 | | | | 1,284,000 | |
| | | | | | | | |
Gross (loss) / profit | | | (53,000 | ) | | | 425,000 | |
| | | | | | | | |
Operating expenses: | | | | | | | | |
Research and development | | | 63,000 | | | | 63,000 | |
Selling and marketing | | | 109,000 | | | | 233,000 | |
General and administrative | | | 715,000 | | | | 1,086,000 | |
| | | 887,000 | | | | 1,382,000 | |
| | | | | | | | |
Operating loss | | (,000) | | | | (957,000 | ) |
| | | | | | | | |
Other (expense) / income : | | | | | | | | |
Interest expense | | | (153,000 | ) | | | (145,000 | ) |
Other income, net | | | 2,000 | | | | 50,000 | |
Income from forgiveness of PPP loan | | | 0 | | | | 335,000 | |
Income from Employee Retention Credit | | | 0 | | | | 581,000 | |
| | | (151,000 | ) | | | 821,000 | |
| | | | | | | | |
Loss before income tax expense | | | (1,091,000 | ) | | | (136,000 | ) |
| | | | | | | | |
Income tax expense | | | (2,000 | ) | | | (2,000 | ) |
| | | | | | | | |
Net loss | | $ | (1,093,000 | ) | | $ | (138,000 | ) |
| | | | | | | | |
Basic and diluted loss per common share | | $ | (0.02 | ) | | $ | (0.00 | ) |
| | | | | | | | |
Weighted average number of shares outstanding – basic & diluted | | | 47,990,417 | | | | 39,281,286 | |
Historical – Nine Months Ended September 30, 2022
Condensed Statements of Cash Flows
(Unaudited) |
| | For The Nine Months Ended | |
| | September 30, | |
| | 2022 | | | 2021 | |
Cash flows from operating activities: | | | | | | |
Net loss | | $ | (1,093,000 | ) | | $ | (138,000 | ) |
Adjustments to reconcile net loss to net cash (used in) operating activities: | | | | | | | | |
Depreciation and amortization | | | 38,000 | | | | 53,000 | |
Penalty added to Cherokee loan balance | | | 0 | | | | 120,000 | |
Recovery of bad debts | | | (1,000 | ) | | | (17,000 | ) |
(Reduction of) / provision for slow moving and obsolete inventory | | | (22,000 | ) | | | 44,000 | |
Employee retention credit | | | 0 | | | | (537,000 | ) |
Shares issued for services | | | 15,000 | | | | 0 | |
Interest paid with restricted stock | | | 0 | | | | 36,000 | |
Forgiveness of PPP loan | | | 0 | | | | (332,000 | ) |
Forgiveness of PPP loan interest | | | 0 | | | | (3,000 | ) |
Changes in: | | | | | | | | |
Accounts receivable | | | 285,000 | | | | (121,000 | ) |
Inventory | | | 85,000 | | | | 73,000 | |
Employee retention credit refund | | | 198,000 | | | | 0 | |
Prepaid expenses and other current assets | | | 0 | | | | 73,000 | |
Right of use asset | | | 18,000 | | | | 26,000 | |
Accounts payable | | | 268,000 | | | | 90,000 | |
Accrued expenses and other current liabilities | | | 77,000 | | | | (149,000 | ) |
Right of use liability | | | (18,000 | ) | | | (27,000 | ) |
Wages payable | | | (7,000 | ) | | | (24,000 | ) |
Net cash used in operating activities | | | (157,000 | ) | | | (833,000 | ) |
Cash flows from financing activities: | | | | | | | | |
Proceeds from debt financing | | | 280,000 | | | | 0 | |
Repayments of debt financing | | | (50,000 | ) | | | (25,000 | ) |
Proceeds from Lincoln Park financing | | | 0 | | | | 632,000 | |
Proceeds from line of credit | | | 901,000 | | | | 1,712,000 | |
Repayments of line of credit | | | (1,079,000 | ) | | | (1,543,000 | ) |
Net cash provided by financing activities | | | 52,000 | | | | 776,000 | |
Net change in cash and cash equivalents | | | (105,000 | ) | | | (57,000 | ) |
Cash and cash equivalents - beginning of period | | | 115,000 | | | | 98,000 | |
Cash and cash equivalents - end of period | | $ | 10,000 | | | $ | 41,000 | |
Supplemental disclosures of cash flow information | | | | | | | | |
Non-Cash transactions | | | | | | | | |
Interest paid with restricted stock | | $ | 0 | | | $ | 36,000 | |
Forgiveness of PPP loan principal and interest | | $ | 0 | | | $ | 335,000 | |
Cash paid during period for interest | | $ | 143,000 | | | $ | 142,000 | |
Cash paid during period for taxes | | $ | 2,000 | | | $ | 2,000 | |
Historical – Nine Months Ended September 30, 2022
Statements of Changes in Stockholders’ Deficit
Statements of Changes in Stockholders’ Deficit |
(Unaudited) |
| | Common Stock | | | Additional Paid-in | | | Accumulated | | | | |
| | Shares | | | Amount | | | Capital | | | Deficit | | | Total | |
Balance – January 1, 2022 | | | 47,598,476 | | | $ | 476,000 | | | $ | 22,393,000 | | | $ | (22,813,000 | ) | | $ | (944,000 | ) |
Shares issued in connection with Landmark consulting agreement | | | 500,000 | | | | 5,000 | | | | 10,000 | | | | | | | | 15,000 | |
Net loss | | | | | | | | | | | | | | | (1,093,000 | ) | | | (1,093,000 | ) |
Balance – September 30, 2022 | | | 48,098,476 | | | $ | 481,000 | | | $ | 22,403,000 | | | $ | (24,906,000 | ) | | $ | (2,022,000 | ) |
| | | | | | | | | | | | | | | | | | | | |
Balance January 1, 2021 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (23,350,000 | ) | | $ | (1,256,000 | ) |
Shares issued to Lincoln Park for balance of Initial Purchase under the 2020 Lincoln Park Equity Line | | | 500,000 | | | | 5,000 | | | | 120,000 | | | | | | | | 125,000 | |
Shares issued to Lincoln Park for purchases under the 2020 Lincoln Park Equity Line | | | 5,800,000 | | | | 58,000 | | | | 449,000 | | | | | | | | 507,000 | |
Shares issued for Cherokee interest in lieu of cash | | | 895,000 | | | | 9,000 | | | | 27,000 | | | | | | | | 36,000 | |
Net loss | | | | | | | | | | | | | | | (138,000 | ) | | | (138,000 | ) |
Balance – September 30, 2021 | | | 44,898,476 | | | $ | 449,000 | | | $ | 22,313,000 | | | $ | (23,488,000 | ) | | $ | (726,000 | ) |
Historical – Nine Months Ended September 30, 2022
Notes to Financial Statements
Note A - Basis of Reporting
The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at September 30, 2022, and the results of operations for the three and nine month periods ended September 30, 2022 and September 30, 2021 and cash flows for the nine month periods ended September 30, 2022 and September 30, 2021.
Operating results for the nine months ended September 30, 2022 are not necessarily indicative of results that may be expected for the year ending December 31, 2022. Amounts at December 31, 2021 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
During the nine months ended September 30, 2022, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. Our independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances, together with cash generated from future operations and amounts available under the Company’s credit facilities are not currently sufficient to fund operations through November 2023.
Throughout most of the nine months ended September 30, 2022, the Company had a line of credit with Crestmark Bank. The maximum availability on the Company’s line of credit was $1,000,000. However, because the amount available under the line of credit is based upon the Company’s accounts receivable, the amounts actually available under the line of credit (historically) have been significantly less than the maximum availability. On September 29, 2022, we paid off the balance of our line of credit ($34,000) with the proceeds of a $40,000 loan from an unaffiliated third party. See Note I – Subsequent Events.
The Company’s credit facilities with Cherokee Financial, LLC (“Cherokee”) matured/expired on February 15, 2022 with a final balloon payment due of $1,240,000. On June 14, 2022, Cherokee agreed that they would defer the principal amounts due under the facilities until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remains current on the quarterly interest payments. Furthermore, any penalties will also be waived if the principal amounts are paid on or prior to February 15, 2023.
The Company’s total debt at September 30, 2022 with Cherokee is $1,240,000. The Company does not expect cash from operations within the next 12 months to be sufficient to pay the amounts due under these credit facilities so, the Company is currently evaluating alternatives to pay off or refinance these facilities.
As discussed in more detail in “Cash Flow, Outlook/Risk”, if sales levels continue to decline further, the Company will continue to have inadequate cash flow and will not be able to satisfy its working capital and any capital expenditure requirements. The Company would then be required to obtain additional credit facilities, sell additional equity securities, or delay capital expenditures and/or reduce or terminate operations, which would have a material adverse effect on the business. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all or continue its operations.
Recently Adopted Accounting Standards
ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), issued in May 2021, addresses an issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2021-04 on January 1, 2022 and the adoption did not have an impact on the Company’s financial condition or results of operations.
ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, issued in November 2021 requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The Company adopted ASU 2021-10 on January 1, 2022 and the adoption did not have an impact on our financial condition or results of operations as ASU-2021-10 only impacts annual financial statement footnote disclosures.
Accounting Standards Issued; Not Yet Adopted
ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, issued in September 2022, requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. ASU 2022-04 becomes effective on January 1, 2023. Early adoption is permitted. The Company does not expect the adoption of ASU 2022-04 to have an impact on its financial condition or results of operations as the Company does not (and has not historically) utilized supplier finance programs in connection with the purchase of goods and services.
ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03.
Note B – Inventory
Inventory is comprised of the following:
| | September 30, 2022 | | | December 31, 2021 | |
| | | | | | |
Raw Materials | | $ | 456,000 | | | $ | 462,000 | |
Work In Process | | | 93,000 | | | | 109,000 | |
Finished Goods | | | 87,000 | | | | 150,000 | |
Allowance for slow moving and obsolete inventory | | | (256,000 | ) | | | (278,000 | ) |
| | $ | 380,000 | | | $ | 443,000 | |
Note C – Net Loss Per Common Share
Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net income per common share includes the weighted average dilutive effect of stock options and warrants. When the Company has a loss, option and warrants are not included as they would be anti-dilutive. Potential common shares outstanding as of September 30, 2022 and 2021:
| | September 30, 2022 | | | September 30, 2021 | |
Options | | | 1,736,000 | | | | 1,937,000 | |
Total | | | 1,736,000 | | | | 1,937,000 | |
Note D – Litigation/Legal Matters
From time to time, the Company may be involved in immaterial legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such immaterial litigation cannot be predicted, if the Company is unsuccessful in defending any such litigation, the resulting financial losses are not expected to have a material adverse effect on the financial position, results of operations or cash flows of the Company.
Property Taxes: The Company is currently delinquent in its property and school taxes. The Company has been communicating with the county over the past several months to discuss options for payment of the delinquent taxes; including, but not limited to, entering into a payment plan offered by the county.
Note E – Line of Credit and Debt
The Company’s Line of Credit and Debt consisted of the following as of September 30, 2022 and December 31, 2021:
| | September 30, 2022 | | | December 31, 2021 | |
Loan and Security Agreement with Cherokee Financial, LLC: 5 year note executed on February 15, 2015, at a fixed annual interest rate of 8% plus a 1% annual oversight fee, interest and oversight fee paid quarterly with principal due on February 15, 2020. Loan was extended for one year (until February 15, 2021) under the same terms and conditions as the original loan. The loan was further extended in February 2021 to February 15, 2022 with $100,000 added to the loan principal as a penalty and the annual interest rate increased to 10%. Loan was further extended in June 2022 (until February 15, 2023). Loan is collateralized by a first security interest in building, land and machinery & equipment. | | $ | 1,000,000 | | | $ | 1,000,000 | |
Crestmark Line of Credit: Line of credit maturing on June 22, 2023 with interest payable at a variable rate based on WSJ Prime plus 3% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Loan was collateralized by first security interest in receivables, inventory and all other assets. Line of credit was paid off on September 29, 2022 with the proceeds of a loan with an unaffiliated third party. | | | 0 | | | | 178,000 | |
2019 Term Loan with Cherokee Financial, LLC: Note at an annual fixed interest rate of 18% paid quarterly in arrears and a balloon payment due on February 15, 2020. Loan was extended in February 2020, until February 15, 2021 with a penalty of $20,000 added to the loan principal and, extended again in February 2021 to February 15, 2022 with another penalty of $20,000 added to the loan principal. Loan was extended in June 2022 (until February 15, 2023). | | | 240,000 | | | | 240,000 | |
November 2020 Shareholder Note: Term loan at 7% interest with the first interest only payment being made on February 4, 2021 and the final interest and $50,000 principal due on November 4, 2022. | | | 50,000 | | | | 50,000 | |
December 2021 Shareholder Note: Term loan with one non-affiliated shareholder at 7% interest until the loan is paid in full. Loan was amended to address additional amounts (totaling $240,000) provided under the loan. | | | 265,000 | | | | 75,000 | |
September 2022 Loan & Promissory Note: Term loan with an unaffiliated third party at a fixed rate of 1% per month, compounded monthly. Loan is collateralized by first security interest in receivables, inventory and all other assets. Principal and accrued interest due on March 28, 2023. | | | 40,000 | | | | 0 | |
Total Debt | | $ | 1,595,000 | | | $ | 1,543,000 | |
Current portion | | $ | 1,595,000 | | | $ | 1,543,000 | |
LOAN AND SECURITY AGREEMENT (LSA) WITH CHEROKEE FINANCIAL, LLC (“CHEROKEE”)
On March 26, 2015, the Company entered into a LSA with Cherokee (the “Cherokee LSA”) in the amount of $1,200,000. The Cherokee LSA reached maturity on February 15, 2020 with a balance of $900,000 (after 4 principal reduction payments of $75,000 each were made over the course of the initial term). In February 2020, the Cherokee LSA was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension.
In February 2021, the Cherokee LSA was further extended for another year, or until February 15, 2022 (the “February 2021 Extension”). Under the February 2021 Extension, the principal of the Cherokee LSA was increased to $1,000,000 to include a $100,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. The annual interest rate on the Cherokee LSA was also increased to a fixed rate of 10% (the prior fixed rate was 8%) plus a 1% annual oversight fee (that remained unchanged). Interest and the oversight fee were still due quarterly.
Cantone Research, Inc. earned a 3% fee on the extended principal of $900,000 (or $27,000) for their services related to securing the February 2021 Extension with Cherokee investors. The fee paid to Cantone Research, Inc. was recorded as a bank fee and is included in general and administrative expenses in the nine months ended September 30, 2021. The Company also paid Cherokee’s legal fees in the amount of $1,000.
On August 18, 2021, we issued 625,000 restricted shares of common stock to Cherokee in lieu of paying the $25,000 August 2021 interest payment in cash. The closing price of the Company’s common shares on the date of the payment in lieu of cash was $0.04.
Under the terms of the February 2021 Extension, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($1,000,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the Cherokee LSA until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments. Furthermore, any penalties will also be waived if the principal amounts are paid on or prior to February 15, 2023.
The debt with Cherokee is collateralized by a first security interest in real estate and machinery and equipment.
In the event of default, including the Company’s inability to make any payments due under the Cherokee LSA (as amended), Cherokee has the right to increase the interest rate on the financing to 18%. As of the date of this report, the Company is current in its interest and administrative fee payments and the Company will continue to make interest and administrative fee payment quarterly on the Cherokee LSA until its maturity in February 2023. The Company can pay off the Cherokee loan at any time with no penalty; except that a 1% administration fee would be required to be paid to Cherokee to close out all participations.
The Company recognized $75,000 in interest expense related to the Cherokee LSA in the nine months ended September 30, 2022 and $73,000 in interest expense related to the Cherokee LSA in the nine months ended September 30, 2021. The Company recognized $25,000 in interest expense related to the Cherokee LSA in the three months ended September 30, 2022and $25,000 in interest expense related to the Cherokee LSA in the three months ended September 30, 2021.
The Company had $8,000 in accrued interest expense at September 30, 2022 related to the Cherokee LSA.
As of September 30, 2022 and December 31, 2021, the balance of the Cherokee LSA was $1,000,000.
LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”)
On June 29, 2015 (the “Closing Date”), the Company entered into a Loan and Security Agreement (“LSA”) with Crestmark related to a revolving line of credit (the “Crestmark LOC”). The Crestmark LOC was used for working capital and general corporate purposes. Upon completion of the initial 5 year term, the Crestmark LOC automatically renewed for additional one (1) year terms unless notice of termination from the Company was received by Crestmark not less than sixty (60) days prior to the end of the renewal term. On September 29, 2022, the Company made a payment to Crestmark in the amount of $34,000 which paid off the balance on the Crestmark LOC.
The Crestmark LOC was secured by a first security interest in the Company’s inventory, receivables and security interest in all other assets of the Company (in accordance with permitted prior encumbrances). Although secured by the assets previously indicated, the Crestmark LOC was a receivables-based only line of credit and the maximum availability (“Maximum Amount”) under the Crestmark LOC was $1,000,000. The Crestmark LOC had a minimum loan balance requirement of $500,000. Throughout the three and nine months ended September 30, 2022 (and until the Company paid off the Crestmark LOC on September 29, 2022), the Company did not meet the minimum loan balance requirement. Under the LSA, Crestmark had the right to calculate interest on the minimum balance requirement rather than the actual balance on the Crestmark LOC (and they were exercising that right).
Interest on the Crestmark LOC was at a variable rate based on the Prime Rate plus 3% with a floor of 5.25%. As of September 29, 2022 (the payoff date), the interest only rate on the Crestmark LOC was 9.25%. As of September 29, 2022 (the payoff date), with all fees considered (the interest rate + an Annual Loan Fee of $7,500 + a monthly maintenance fee of 0.30% of the actual average monthly balance from the prior month), the interest rate on the Crestmark LOC was 16.38%.
The Company incurred $35,000 in interest expense in the nine months ended September 30, 2022 and $38,000 in interest expense related to the Crestmark LOC in the nine months ended September 30, 2021. The Company incurred $13,000 in interest expense in the three months ended September 30, 2022 and $13,000 in interest expense in the three months ended September 30, 2021. The Crestmark LOC was paid off on September 29, 2022 so, the Company had $0 in accrued interest expense related to the Crestmark LOC at September 30, 2022.
At September 30 2022, the balance on the Crestmark LOC was $0 and as of December 31, 2021, the balance on the Crestmark LOC was $178,000.
2019 TERM LOAN WITH CHEROKEE
In February 2019, the Company entered into an agreement with Cherokee under which Cherokee provided the Company with a loan in the amount of $200,000 (the “2019 Cherokee Term Loan”). The annual interest rate under the 2019 Cherokee Term Loan is 18% (fixed) paid quarterly in arrears.
In February 2020, the 2019 Cherokee Term Loan was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension. For consideration of this extension, the Company issued 1.5% of the $200,000 principal, or $3,000, in 42,857 restricted shares of the Company’s common stock to Cherokee. The Company also incurred a penalty in the amount of $20,000 which was added to the principal balance of the 2019 Cherokee Term Loan; bringing the principal to $220,000.
In February 2021, the 2019 Cherokee Term Loan was further extended to February 15, 2022. Under the terms of this additional extension, the 2019 Cherokee Term Loan was increased to $240,000 to include a $20,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. In addition, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee may charge an 8% delinquent fee on the principal balance ($240,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the 2019 Cherokee Term Loan until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments. Furthermore, any penalties will also be waived if the principal amounts are paid on or prior to February 15, 2023.
In the event of default, this includes, but is not limited to, the Company’s inability to make any payments due under the 2019 Cherokee Term Loan; Cherokee has the right to increase the interest rate on the 2019 Cherokee Term Loan to 20%.
The Company recognized $32,000 in interest expense related to the 2019 Cherokee Term Loan in both the nine months ended September 30, 2022 and the nine months ended September 30, 2021. The Company recognized $11,000 in interest expense related to the 2019 Cherokee Term Loan in both the three months ended September 30, 2022 and the three months ended September 30, 2021. The Company had $4,000 in accrued interest expense at September 30, 2022.
The balance on the 2019 Cherokee Term Loan was $240,000 at September 30, 2022 and at December 31, 2021.
NOVEMBER 2020 TERM LOAN
On November 4, 2020, the Company entered into a loan agreement with an individual shareholder in the principal amount of $50,000. There were no expenses related to the term loan and the interest rate is 7%. The first interest only payment was paid on February 4, 2021 and the final interest payment and principal was due on May 4, 2021. On May 4, 2021, the Company extended this loan for another 6 months, or until November 4, 2021. The interest rate and all other terms of the note remained unchanged under this extension.
On November 4, 2021, the November 2020 Term Loan was extended again. Under this extension, the principal was due on November 4, 2022. The last interest payment made to the shareholder was in November 2021 and was for the period of August 5, 2021 through November 4, 2021. The shareholder agreed to defer the quarterly interest payments due on the extended facility. The facility was further extended on November 4, 2022, under the same terms and conditions, for another 6 months. Therefore, interest accruing on the November 2020 Term Loan from November 5, 2021 until May 4, 2023 would be paid upon maturity of the loan along with the principal. Provided no further funds are loaned under the facility and no payments are made on the loan, including a complete payoff, the interest due on May 4, 2023 would be $5,000. At September 30, 2022, the interest due on this loan is $3,000.
The Company recognized $3,000 of interest expense related to the November 2020 Term Loan in the nine months ended September 30, 2022 and $2,000 of interest expense in the nine months ended September 30, 2021. The Company recognized $1,000 of interest expense related to the November 2020 Term Loan in both the three months ended September 30, 2022 and in the three months ended September 30, 2021.
The Company had $3,000 in accrued interest expense related to this loan as of September 30, 2022.
The balance on the November 2020 Term Loan was $50,000 at September 30, 2022 and at December 31, 2021.
DECEMBER 2021 SHAREHOLDER LOAN
On December 14, 2021, the Company entered into Loan Agreements with two non-affiliated shareholders resulting in gross (and net) proceeds of $75,000 as there were no costs associated with the loans. Interest on the loans is 7% per annum until principal and interest were both due in full, or until June 15, 2022. The first interest payments were due on March 15, 2022 and payment of final interest and principal was due June 15, 2022.
One of the loans (in the amount of $25,000) was paid in full on June 13, 2022 along with the final interest payment due.
On April 6, 2022, we amended the loan with the other non-affiliated shareholder. This amendment (No.1; hereinafter referred to in this paragraph as “Amendment No. 1”) increased the principal due to the shareholder by $25,000; bringing their total principal to $75,000. No other terms of the loan were changed under Amendment No. 1.
On April 14, 2022, the loan was amended again (under Amendment No. 2; hereinafter referred to in this paragraph as “Amendment No. 2”) increasing the principal again by $50,000; bringing their total principal to $125,000. No other terms of the loan were changed under Amendment No. 2.
On May 11, 2022, the loan was amended again (under Amendment No. 3; hereinafter referred to in this paragraph as “Amendment No. 3”) increasing the principal again by $75,000; bringing their total principal to $200,000. The loan was further amended to include a specific payment schedule based on receipt of anticipated ERC refunds.
On June 13, 2022, the Company made a principal reduction payment to this shareholder in the amount of $25,000 from proceeds from the ERC refund received on June 2, 2022; bringing the principal amount owed on the loan to $175,000. See Note I – Subsequent Events for more information on this loan.
On July 13, 2022, the loan was amended again (under Amendment No. 4; hereinafter referred to in this paragraph as “Amendment No. 4”) increasing the principal by $25,000; bringing their total principal to $200,000 again. The loan agreement was also amended to revise the maturity date from June 15, 2022 to no specific maturity date.
On September 13, 2022, the loan was amended again (under Amendment No. 5; hereinafter referred to in this paragraph as “Amendment No. 5”) increasing the principal by $25,000; bringing their total principal to $225,000 again.
On September 28, 2022, the shareholder provided the Company with additional funds, $40,000, under this shareholder loan with the understanding that the amount would be paid back once the September 2022 Loan funds were received and there would be no interest charged on this additional amount. This increased the amount due to the shareholder under the facility to $265,000. The Company did pay this additional amount in full on October 4, 2022 as indicated under Note I – Subsequent Events.
The Company incurred $8,000 in interest expense related to these loans in the nine months ended September 30, 2022 and $0 in interest expense in the nine months ended September 30, 2021 (as the facilities were not in place until December 2021). The Company incurred $3,000 in interest expense related to these loans in the three months ended September 30, 2022 and $0 in interest expense in the three months ended September 30, 2021 (as the facilities were not in place until December 2021).
The Company had $1,000 in accrued interest expense at September 30, 2022. The balance on these loans was $265,000 at September 30, 2022 and $75,000 at December 31, 2021. See Note I – Subsequent Event for more information regarding the balance of the loan.
SEPTEMBER 2022 LOAN & PROMISSORY NOTE
On September 28, 2022, the Company entered into a Loan and Promissory with an unaffiliated third party (the “September 2022 Loan”) at a fixed rate of 1% per month, compounded monthly and received gross/net proceeds of $40,000. The Company utilized $34,000 of the loan proceeds to pay off its Crestmark Line of Credit (See Note E – Line of Credit and Debt). The September 2022 Loan is collateralized by a first security interest in the Company’s receivables, inventory and all other assets. Principal and accrued interest is due on March 28, 2023.
OTHER DEBT INFORMATION
In addition to the current debt indicated previously, previous debt facilities had financial impact on the three and/or nine months ended September 30, 2021. More specifically:
SBA PAYCHECK PROTECTION LOAN (PPP LOAN)
On April 22, 2020, the Company entered into a Promissory Note (“PPP Note”) for $332,000 with Crestmark Bank, pursuant to the U.S. Small Business Administration (“SBA”) Paycheck Protection Program under Title I of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act passed by Congress and signed into law on March 27, 2020. The PPP Note was unsecured, with an interest rate of 1.00% per annum, with principal and interest payments deferred for the first six months, and maturity in two years. On June 15, 2021, the Company applied for forgiveness of the PPP loan in the amount of $332,000 under PPP guidelines. Our forgiveness application was reviewed by the SBA and on August 3, 2021, the SBA remitted payment to Crestmark Bank for the balance of the PPP Loan principal and all interest due on the PPP Loan.
The Company recognized $2,000 in interest expense in the nine months ended September 30, 2021 and $1,000 in interest expense in the three months ended September 30, 2021.
NOTE F – Employee Retention Credit
The employee retention credit (“ERC”), as originally enacted on March 27, 2020 by the CARES Act, is a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer pays to employees. On March 1, 2021, the IRS released Notice 2021-20 to provide guidance on the original ERC, as modified by the Relief Act. The Relief Act extended and enhanced the ERC for qualified wages paid after December 31, 2020 through June 30, 2021. Under the Relief Act, eligible employers may claim a refundable tax credit against certain employment taxes equal to 70% of the qualified wages an eligible employer pays to employees after December 31, 2020 through June 30, 2021. Under the American Rescue Plan Act and previously under the Consolidated Appropriations Act, 2021, the ERC was extended and expanded allowing claims through December 31, 2021 by eligible employers who retained employees during the Covid-19 pandemic. However, on November 5, 2021, the House of Representatives passed the Infrastructure Investment and Jobs Act (“Infrastructure Bill”) under which the ERC would terminate as of September 20, 2021 instead of December 31, 2021 and, President Biden signed the bill on November 15, 2021.
The maximum qualified wages for each employee under the current ERC is $10,000 per quarter. Also, because the Company has 100 or fewer full-time employees, health plan expenses borne by the Company can also be included as qualified wages in addition to salary. To qualify for the ERC in 2021, an employer must have experienced at least a 20% reduction in gross receipts when compared to the same quarter in either 2020 or 2019. During the first quarter of 2021, the second quarter of 2021 and the third quarter of 2021, the Company qualified for the ERC when comparing its 2021 quarters with both 2020 and 2019 quarters. In August 2021, the Company’s payroll service provider processed and mailed a Form 941-X to claim a refund in the amount of $202,000 on qualified wages paid in the first quarter of 2021. Due to a change in the Form 941-X, the Company’s payroll service provider did not process and mail its Form 941-X to claim a refund in the amount of $198,000 on qualified wages paid in the second quarter of 2021 until October 28, 2021. In the middle of the third quarter of 2021, the Company began taking the ERC in its current payroll; which reduced payroll by approximately $44,000 in the third quarter of 2021. Given this, the Company did not have to amend its Form 941 for the third quarter of 2021; however the Form 941 claiming a refund in the amount of $137,000 was filed electronically with the IRS on November 1, 2021 by the Company’s payroll service provider. Upon passing of the Infrastructure Bill, the Company ceased taking the ERC in its current payroll.
On December 28, 2021, the Company received its refund for the third quarter of 2021 in the amount of $137,000. Shortly before receiving the first refund, the Company spoke with the Internal Revenue Service (“IRS”) to obtain statuses of our filings. The Company was informed that the IRS did not have record of receiving the Company’s Form 941-X for the first quarter of 2021 (which was mailed by the Company’s service provider in August 2021). The Company re-sent the Form 941-X for the first quarter of 2021 via overnight service on December 31, 2021 and the IRS received it on January 5, 2022. This lack of receipt has resulted in a delay in receiving the expected refund in the amount of $202,000.
On June 2, 2022, the Company received a refund for the second quarter of 2021 in the amount of $199,000. This amount represents the $198,000 claimed as a refund and $1,000 in interest. The Company has had a number of discussions with the IRS and has been given a number of time frames in which the refund for the first quarter of 2021 could be expected. However, the Company has not yet received the refund. Last contact with the IRS was in mid-September 2022 and the Company was informed at that time that the filing was still being processed with no adjustments. The Company’s remaining expected refunds; totaling $202,000, is included on the Condensed Balance Sheets under current assets, as well as on the Company’s Condensed Statements of Operations under other income.
Laws and regulations concerning government programs, including the Employee Retention Credit are complex and subject to varying interpretations. Claims made under the CARES Act may also be subject to retroactive audit and review. There can be no assurance that regulatory authorities will not challenge the Company’s claim to the ERC, and it is not possible to determine the impact (if any) this would have upon the Company.
NOTE G – Stock Options and Warrants
The Company currently has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by our Board of Directors and approved by our shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares.
During the three months ended September 30, 2022 and the three months ended September 30, 2021, the Company issued 0 options to purchase shares of common stock.
Stock option activity for the nine months ended September 30, 2022 and the nine months ended September 30, 2021 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand):
| | Nine months ended September 30, 2022 | | | Nine months ended September 30, 2021 | |
| | Shares | | | Weighted Average Exercise Price | | | Aggregate Intrinsic Value as of September 30, 2022 | | | Shares | | | Weighted Average Exercise Price | | | Aggregate Intrinsic Value as of September 30, 2021 | |
Options outstanding at beginning of year | | | 1,937,000 | | | $ | 0.13 | | | | | | | 1,987,000 | | | $ | 0.13 | | | | |
Granted | | | 0 | | | NA | | | | | | | 0 | | | NA | | | | |
Exercised | | | 0 | | | NA | | | | | | | 0 | | | NA | | | | |
Cancelled/expired | | | (201,000 | ) | | $ | 0.18 | | | | | | | (50,000 | ) | | $ | 0.13 | | | | |
Options outstanding at end of quarter | | | 1,736,000 | | | $ | 0.12 | | | $ | 0 | | | | 1,937,000 | | | $ | 0.13 | | | $ | 0 | |
Options exercisable at end of quarter | | | 1,736,000 | | | $ | 0.12 | | | | | | | | 1,937,000 | | | $ | 0.13 | | | | | |
The Company recognized $0 in share based payment expense in the nine months ended September 30, 2022 and in the nine months ended September 30, 2021. The Company recognized $0 in share based payment expense in the three months ended September 30, 2022 and in the three months ended September 30, 2021. At September 30, 2022, there was $0 of unrecognized share based payment expense related to stock options.
Warrants
There was no warrant activity in the three or nine months ended September 30, 2022 or September 30, 2021.
NOTE H – Changes in Stockholders’ Deficit
LANDMARK CONSULTING AGREEMENT
On March 7, 2022, the Company entered into a Financial Advisory Agreement (the “Agreement”) with Landmark Pegasus, Inc. (‘Landmark”). The Agreement provided that Landmark would provide certain financial advisory services for a minimum period of 3 months (which period commenced on February 28, 2022), and as consideration for these services, the Company would pay Landmark (a) a retainer fee consisting of 500,000 restricted shares of common stock and a warrant to purchase 2.75 million shares of the Company’s common stock at a strike price equal to the average closing price of the Company’s common shares for the 30 days preceding the Agreement, or $0.035 per share, resulting in gross proceeds to the Company in the amount of $96,250. The warrant would vest upon the closing of a transaction involving Landmark or upon the invocation of a “Breakup Fee”.
In a subsequent amendment, the terms of the warrant were changed to reflect that the warrant would be issued immediately preceding the closing of a transaction involving Landmark or immediately upon the invocation of the Breakup Fee. In each case, the warrant would vest immediately (i.e. the warrant would be 100% immediately exercisable).
The Breakup Fee would be invoked upon the generation of a specific transaction to ABMC which meets certain criteria agreed upon by both the Company and Landmark; which transaction is then rejected by the Company. The Company will also pay to Landmark a “Success Fee” for the consummation of a transaction closing during the term of the Agreement and for 12 months thereafter, between the Company and any party first introduced to the Company by Landmark, or with any party the Company has specifically requested that Landmark assistance with the transaction.
Upon invocation of the Breakup Fee or payment of the Success Fee, the Company will also issue an additional 250,000 restricted shares of the Company’s common stock.
In the event that the Company consummates a transaction involving the provision of services to any party introduced to the Company by Landmark or with any party the Company has specifically requested Landmark’s assistance with, the Company will pay Landmark 10% of any revenues received from the transaction, unless this percentage is modified by both the Company and Landmark in writing. There is no material relationship between the Company and Landmark, other than with respect to the Agreement.
As of September 30, 2022 and as of the date of this report, no additional shares or warrants have been issued as the Breakup Fee has not been invoked nor has a Success Fee been required.
LINCOLN PARK EQUITY LINE OF CREDIT – DECEMBER 2020
On December 9, 2020, the Company entered into a Purchase Agreement and a Registration Rights Agreement with Lincoln Park (together the “Agreements”) under which Lincoln Park agreed to purchase from the Company, from time to time, up to $10,250,000 of its shares of common stock, par value $0.01 per share, subject to certain limitations set forth in the Purchase Agreement, during the term of the Purchase Agreement (two years). A Form S-1 Registration Statement was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on January 11, 2021. Under the terms of the Lincoln Park facility, which have been previously disclosed in our periodic reports filed with the SEC, in the nine months ended September 30, 2021, the Company sold 500,000 shares of common stock that represented the balance of an initial purchase and 5,800,000 shares of common stock to Lincoln Park as Regular Purchases. The Company received proceeds of $632,000 from these purchases. The Company did not sell any shares of common stock to Lincoln Park in the nine months ended September 30, 2022 as the closing price of the Company’s shares of common stock did not exceed $0.05 (which is a requirement under the terms of the facility). In fact, the last sale to Lincoln Park was in October 2021.
Note I – Subsequent Events
OCTOBER 2022 LOAN AND PROMISSORY NOTE
On October 3, 2022, we entered into a Loan and Promissory Note (the “October 2022 Loan) with the same unaffiliated third party (the “Holder”) discussed in the September 2022 Loan and Promissory Note (found in Note E). The total principal under the October 2022 Loan is $400,000 and includes the $40,000 that was extended under the September 2022 Loan; thereby cancelling the September 2022 Loan. The October 2022 Loan is at a fixed rate of 1% per month, compounded monthly. The October 2022 Loan is payable in three equal monthly installments of $140,132.50 with the first payment being due on January 28, 2023 and the final payment being due on March 28, 2023 (the maturity date of the facility). The October 2022 Loan is collateralized by a first security interest in the Company’s receivables, inventory and all other assets. If the Holder does not receive any payment when due, we would need to pay a late charge equaling 1% of the overdue amount. The principal may be paid prior to maturity without any premium or penalty. Our CEO Melissa Waterhouse (“Waterhouse”) also provided a Validity Guarantee in connection with the October 2022 Loan. Under the Validity Guarantee, Waterhouse provides representations and warranties with respect to the validity of our financials. Waterhouse did not receive any compensation in connection with providing the required Validity Guarantee.
DECEMBER 2021 SHAREHOLDER LOAN
On October 4, 2022, we paid $40,000 to the shareholder to pay off a short-term loan provided to the Company on September 28, 2022. With this payment, the loan balance under the December 2021 Shareholder Loan is $225,000.
EXTENSION OF THE NJ FACILITY LEASE
On October 27, 2022, we extended the lease of our NJ facility for an additional two months after the term of our current lease (which expires on December 31, 2022), or until February 28, 2023. In connection with the extension, we were required to pay $21,000 to our landlord which, is rent in advance for the months of November 2022 through February 2023 at a higher rate as consideration for the short-term extension.
NOVEMBER 2020 TERM LOAN
On November 4, 2022, the November 2020 Term Loan was further extended under the same terms and conditions for another 6 months, or until May 4, 2023.
Note J – Income Taxes
The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of net, deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. With regards to the use of net losses incurred for 2018 and later, such net operating losses have no expiration date, while net operating loss carryforwards can only be used to offset up to 80% of taxable income. Net operating losses incurred prior to 2018 may be fully utilized to offset taxable income, but expire in 20 years.
A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows:
| | Quarter Ended September 30, 2022 | | | Quarter Ended September 30, 2021 | |
Tax expense at federal statutory rate | | (21 | %) | | (21 | %) |
State tax expense, net of federal tax effect | | | 0 | % | | | 0 | % |
Increase in valuation allowance | | | 21 | % | | | 21 | % |
Effective income tax rate | | (0 | %) | | (0 | %) |
Deferred income taxes reflect the temporary differences between the financial statement carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, adjusted by the relevant tax rate. The components of deferred tax assets and liabilities are as follows:
| | September 30, 2022 | | | December 31, 2021 | |
| | | | | | |
Inventory capitalization | | $ | 0 | | | $ | 8,000 | |
Inventory allowance | | | 66,000 | | | | 72,000 | |
Allowance for doubtful accounts | | | 1,000 | | | | 1,000 | |
Accrued compensation | | | 18,000 | | | | 18,000 | |
Stock based compensation | | | 149,000 | | | | 160,000 | |
Deferred wages payable | | | 19,000 | | | | 21,000 | |
Depreciation – Property, Plant & Equipment | | | (19,000 | ) | | | (24,000 | ) |
Research and development credits | | | 24,000 | | | | 24,000 | |
Net operating loss carry-forwards | | | 2,916,000 | | | | 2,631,000 | |
Total deferred income tax assets, net | | | 3,174,000 | | | | 2,911,000 | |
Less: valuation allowance | | | (3,174,000 | | | | (2,911,000 | ) |
Net deferred income tax assets | | $ | 0 | | | $ | 0 | |
The valuation allowance for deferred income tax assets was $3,174,000 as of September 30, 2022 and $2,911,000 as of December 31, 2021. The net change in the deferred income tax assets valuation allowance was $263,000 for the nine months ended September 30, 2022. The Company believes that it is more likely than not that the deferred tax assets will not be realized.
As of September 30, 2022, the prior full three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes.
At September 30, 2022, the Company had Federal and state net operating loss carry-forwards for income tax purposes of approximately $11,214,000 and research and development credits of $24,000. The Company’s net operating loss carry-forwards began to expire in 2022 and continue to expire through 2037. Net operating losses incurred from 2018 to date have no expiration date. In assessing the reliability of deferred income tax assets, management considers whether or not it is more likely than not that some portion or all deferred income tax assets, net, will be realized. The ultimate realization of net deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment.
UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS
The following unaudited pro forma financial statements are derived from the historical financial statements of ABMC as of and for year ended December 31, 2021 and the nine months ended September 30, 2022. The unaudited pro forma financial statements are presented to reflect adjustments to ABMC’s financial statements as if the Asset Sale were completed on January 1, 2021. The unaudited pro forma financial statements have been presented for informational purposes only. The assumptions used and pro forma adjustments derived from such assumptions are based on currently available information, and ABMC believes such assumptions are reasonable under the circumstances. The pro forma data is not necessarily indicative of ABMC’s results of operations or financial condition had the Asset Sale been completed on the dates assumed. In addition, they are not necessarily indicative of our future results of operations or financial condition.
PRO FORMA – Year Ended December 31, 2021
Balance Sheets
| | December 31, | | | December 31, | |
| | 2021 | | | 2020 | |
| | (unaudited) | |
ASSETS | | | | | | |
Current assets | | | | | | |
Cash and cash equivalents | | $ | 1,056,000 | | | $ | 98,000 | |
Accounts receivable, net of allowance for doubtful accounts of $0 at December 31, 2021 and $22,000 at December 31, 2020 | | | 0 | | | | 407,000 | |
Inventory, net of allowance of $0 at December 31, 2021 and $279,000 at December 31, 2020 | | | 0 | | | | 536,000 | |
Prepaid expenses and other current assets | | | 0 | | | | 104,000 | |
Right of use asset – operating leases | | | 0 | | | | 35,000 | |
Total current assets | | | 1,056,000 | | | | 1,180,000 | |
Property, plant and equipment, net | | | 0 | | | | 576,000 | |
Patents, net | | | 0 | | | | 108,000 | |
Right of use asset – operating leases | | | 0 | | | | 41,000 | |
Other assets | | | 0 | | | | 21,000 | |
Total assets | | $ | 1,056,000 | | | $ | 1,926,000 | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | | | | | | | | |
Current liabilities | | | | | | | | |
Accounts payable | | $ | 87,000 | | | $ | 577,000 | |
Accrued expenses and other current liabilities | | | 229,000 | | | | 620,000 | |
Right of use liability – operating leases | | | 0 | | | | 33,000 | |
Wages payable | | | 0 | | | | 107,000 | |
Line of credit | | | 0 | | | | 277,000 | |
PPP loan | | | 0 | | | | 332,000 | |
Current portion of long-term debt, net of deferred finance costs | | | 0 | | | | 75,000 | |
Total current liabilities | | | 316,000 | | | | 2,021,000 | |
Long-term debt/other liabilities, net of current portion and deferred financing costs | | | 0 | | | | 1,120,000 | |
Right of use liability – operating leases | | | 0 | | | | 41,000 | |
Total liabilities | | | 316,000 | | | | 3,182,000 | |
COMMITMENTS AND CONTINGENCIES | | | | | | | | |
Stockholders’ (deficit): | | | | | | | | |
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding | | | 0 | | | | 0 | |
Common stock; par value $.01 per share; 50,000,000 shares authorized; 37,703,476 issued and outstanding as of December 31, 2021 and as of December 31, 2020 | | | 377,000 | | | | 377,000 | |
Additional paid-in capital | | | 21,717,000 | | | | 21,717,000 | |
Accumulated deficit | | | (21,354,000 | ) | | | (23,350,000 | ) |
Total stockholders’ equity / (deficit) | | | 740,000 | | | | (1,256,000 | ) |
Total liabilities and stockholders’ equity / (deficit) | | $ | 1,056,000 | | | $ | 1,926,000 | |
PRO FORMA – Year Ended December 31, 2021
Statements of Operations
| | Year Ended December 31, | |
| | 2021 | | | 2020 | |
| | (unaudited) | |
| | | | | | |
Revenue, net | | $ | 0 | | | $ | 4,147,000 | |
| | | | | | | | |
Cost of goods sold | | | 0 | | | | 2,909,000 | |
| | | | | | | | |
Gross profit | | | 0 | | | | 1,238,000 | |
| | | | | | | | |
Operating expenses: | | | | | | | | |
Research and development | | | 0 | | | | 90,000 | |
Selling and marketing | | | 0 | | | | 493,000 | |
General and administrative | | | 163,000 | | | | 1,276,000 | |
| | | 163,000 | | | | 1,859,000 | |
| | | | | | | | |
Operating loss | | | (163,000 | ) | | | (621,000 | ) |
| | | | | | | | |
Other income / (expense): | | | | | | | | |
Interest expense | | | 0 | | | | (175,000 | ) |
Other income, net | | | 0 | | | | 2,000 | |
Gain on asset sale | | | 1,824,000 | | | | 0 | |
Gain on forgiveness of PPP loan | | | 335,000 | | | | 0 | |
Total other income / (expense) | | | 2,159,000 | | | | (173,000 | ) |
| | | | | | | | |
Income / (loss) before income tax expense | | | 1,996,000 | | | | (794,000 | ) |
| | | | | | | | |
Income tax expense | | | 0 | | | | (2,000 | ) |
| | | | | | | | |
Net income / (loss) | | $ | 1,996,000 | | | $ | (796,000 | ) |
| | | | | | | | |
Basic and diluted income / (loss) per common share | | $ | 0.05 | | | $ | (0.02 | ) |
| | | | | | | | |
Weighted average number of shares outstanding – basic and diluted | | | 35,558,105 | | | | 35,558,105 | |
PRO FORMA – Year Ended December 31, 2021
Statements of Cash Flows
| | Year Ended | | | Year Ended | |
| | December 31, | | | December 31, | |
| | 2021 | | | 2020 | |
| | (unaudited) | |
Cash flows from operating activities: | | | | | | |
Net income / (loss) | | $ | 1,996,000 | | | $ | (796,000 | ) |
Adjustments to reconcile net income / (loss) to net cash provided by / (used in) operating activities: | | | | | | | | |
Depreciation and amortization | | | 0 | | | | 79,000 | |
Amortization of debt issuance costs | | | 0 | | | | 17,000 | |
Non-cash loan penalty | | | 0 | | | | 20,000 | |
Bad debt (reduction) expense | | | 0 | | | | 3,000 | |
Provision for slow moving and obsolete inventory | | | 0 | | | | 157,000 | |
Share-based payment expense | | | 0 | | | | 2,000 | |
Director fee paid with restricted stock | | | 0 | | | | 31,000 | |
Refinance fee paid with restricted stock | | | 0 | | | | 21,000 | |
Changes in: | | | | | | | | |
Accounts receivable | | | (407,000 | ) | | | (40,000 | ) |
Inventory | | | (815,000 | ) | | | 117,000 | |
Prepaid expenses and other current assets | | | 104,000 | | | | (37,000 | ) |
Accounts payable | | | (490,000 | ) | | | (75,000 | ) |
Accrued expenses and other current liabilities | | | (238,000 | ) | | | 15,000 | |
Wages payable | | | (36,000 | ) | | | 3,000 | |
Net cash provided by / (used in) operating activities | | | 114,000 | | | | (483,000 | ) |
Cash flows from investing activities: | | | | | | | | |
Sale of property, plant, and equipment | | | (576,000 | ) | | | (4,000 | ) |
Sale of Patent Asset | | | (108,000 | ) | | | 0 | |
Net cash used in investing activities | | | (684,000 | ) | | | (4,000 | ) |
Cash flows from financing activities: | | | | | | | | |
Proceeds from debt financing | | | 0 | | | | 75,000 | |
Payments on debt financing | | | (1,472,000 | ) | | | (42,000 | ) |
Proceeds from private placement | | | 0 | | | | 199,000 | |
Proceeds from Lincoln Park financing | | | 0 | | | | 125,000 | |
Proceeds from Asset Sale | | | 3,000,000 | | | | 0 | |
Expenses from Lincoln Park financing | | | 0 | | | | (48,000 | ) |
Proceeds from lines of credit | | | 0 | | | | 3,949,000 | |
Payments on lines of credit | | | 0 | | | | (4,009,000 | ) |
Net cash provided by financing activities | | | 1,528,000 | | | | 581,000 | |
Net increase in cash and cash equivalents | | | 958,000 | | | | 94,000 | |
Cash and cash equivalents – beginning of period | | | 98,000 | | | | 4,000 | |
Cash and cash equivalents – end of period | | $ | 1,056,000 | | | $ | 98,000 | |
Supplemental disclosures of cash flow information: | | | | | | | | |
Non-Cash transactions: | | | | | | | | |
Loans converted to stock | | $ | 0 | | | $ | 35,000 | |
Commitment shares issued to Lincoln park, charged to Paid in Capital | | $ | 0 | | | $ | 138,000 | |
Patent asset impairment | | $ | 0 | | | $ | 0 | |
Cash paid during the year for interest | | $ | 0 | | | $ | 152,000 | |
Cash paid for taxes | | | 0 | | | $ | 2,000 | |
PRO FORMA – Year Ended December 31, 2021
Statements of Changes in Stockholders’ Equity / (Deficit)
PRO FORMA - Statements of Changes in Stockholders’ Equity / (Deficit) (unaudited) |
| | Common Stock | | | Additional Paid-in | | | Accumulated | | | | |
| | Shares | | | Amount | | | Capital | | | Deficit | | | Total | |
Balance – January 1, 2020 | | | 32,680,984 | | | $ | 327,000 | | | $ | 21,437,000 | | | $ | (22,554,000 | ) | | $ | (790,000 | ) |
Shares issued to Cherokee in connection with loan | | | 300,000 | | | | 3,000 | | | | 18,000 | | | | | | | | 21,000 | |
Shares issued under February 2020 Private Placement | | | 2,842,856 | | | | 28,000 | | | | 171,000 | | | | | | | | 199,000 | |
Shares issued to Lincoln Park for Initial Purchase under the 2020 Lincoln Park equity line | | | 500,000 | | | | 5,000 | | | | 120,000 | | | | | | | | 125,000 | |
Shares issued to Lincoln Park for commitment under the 2020 Lincoln Park equity line | | | 1,250,000 | | | | 13,000 | | | | 125,000 | | | | | | | | 138,000 | |
Non cash costs of commitment shares under Lincoln Park equity line | | | | | | | | | | | (138,000 | ) | | | | | | | (138,000 | ) |
Expenses related to the 2020 Lincoln Park equity line | | | | | | | | | | | (48,000 | ) | | | | | | | (48,000 | ) |
Shares issued for board meeting attendance in lieu of cash | | | 129,636 | | | | 1,000 | | | | 30,000 | | | | | | | | 31,000 | |
Share based payment expense | | | | | | | | | | | 2,000 | | | | | | | | 2,000 | |
Net loss | | | | | | | | | | | | | | | (796,000 | ) | | | (796,000 | ) |
Balance – December 31, 2020 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (23,350,000 | ) | | $ | (1,256,000 | ) |
Net income | | | | | | | | | | | | | | | 1,996,000 | | | | 1,996,000 | |
Balance – December 31, 2021 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (21,354,000 | ) | | $ | 740,000 | |
PRO FORMA – Nine Months Ended September 30, 2022
Condensed Balance Sheets
| | September 30, | | | December 31, | |
| | 2022 | | | 2021 | |
ASSETS | | (Unaudited) | |
Current assets | | | | | | |
Cash and cash equivalents | | $ | 855,000 | | | $ | 1,056,000 | |
Total current assets | | | 855,000 | | | | 1,056,000 | |
Total assets | | $ | 855,000 | | | $ | 1,056,000 | |
| | | | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | |
Current liabilities | | | | | | | | |
Accounts payable | | $ | 0 | | | $ | 87,000 | |
Accrued expenses and other current liabilities | | | 229,000 | | | | 229,000 | |
Total current liabilities | | | 229,000 | | | | 316,000 | |
Total liabilities | | | 229,000 | | | | 316,000 | |
COMMITMENTS AND CONTINGENCIES | | | | | | | | |
Stockholders' deficit: | | | | | | | | |
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at September 30, 2022 and December 31, 2021 | | | 0 | | | | 0 | |
Common stock; par value $.01 per share; 75,000,000 shares authorized; 37,703,476 issued and outstanding as of September 30, 2022 and as of December 31, 2021 | | | 377,000 | | | | 377,000 | |
Additional paid-in capital | | | 21,717,000 | | | | 21,717,000 | |
Accumulated Deficit | | | (21,468,000 | ) | | | (21,354,000 | ) |
Total stockholders’ equity | | | 626,000 | | | | 740,000 | |
Total liabilities and stockholders’ equity | | $ | 855,000 | | | $ | 1,056,000 | |
PRO FORMA – Nine Months Ended September 30, 2022
Condensed Statements of Operations
(Unaudited) |
| | For The Nine Months Ended | |
| | September 30, | |
| | 2022 | | | 2021 | |
| | (unaudited) | |
| | | | | | |
Net sales | | $ | 0 | | | $ | 0 | |
| | | | | | | | |
Cost of goods sold | | | 0 | | | | 0 | |
| | | | | | | | |
Gross profit | | | 0 | | | | 0 | |
| | | | | | | | |
Operating expenses: | | | | | | | | |
Research and development | | | 0 | | | | 0 | |
Selling and marketing | | | 0 | | | | 0 | |
General and administrative | | | 114,000 | | | | 108,000 | |
| | | 114,000 | | | | 108,000 | |
| | | | | | | | |
Operating loss | | | (114,000 | ) | | | 108,000 | ) |
| | | | | | | | |
Other (expense) / income : | | | | | | | | |
Gain on asset sale | | | 0 | | | | 1,824,000 | |
Total other income | | | 0 | | | | 1,824,000 | |
| | | | | | | | |
(Loss) / income before income tax expense | | | (114,000 | ) | | | 1,716,000 | |
| | | | | | | | |
Net (loss) / income | | $ | (114,000 | ) | | $ | 1,716,000 | |
| | | | | | | | |
Basic and diluted (loss) / income per common share | | $ | - | | | $ | - | |
| | | | | | | | |
Weighted average number of shares outstanding – basic & diluted | | | 35,558,105 | | | | 35,558,105 | |
PRO FORMA – Nine Months Ended September 30, 2022
Condensed Statements of Cash Flows
(Unaudited) |
| | For The Nine Months Ended | |
| | September 30, | |
| | 2022 | | | 2021 | |
Cash flows from operating activities: | | | | | | |
Net (loss) / income | | $ | (114,000 | ) | | $ | 2,037,000 | |
Adjustments to reconcile net loss to net cash (used in) / provided by operating activities: | | | | | | | | |
Changes in: | | | | | | | | |
Accounts receivable | | | 0 | | | | (407,000 | ) |
Inventory | | | 0 | | | | (815,000 | ) |
Employee retention credit refund | | | 0 | | | | | |
Prepaid expenses and other current assets | | | 0 | | | | 104,000 | |
Accounts payable | | | (87,000 | ) | | | (432,000 | ) |
Accrued expenses and other current liabilities | | | 0 | | | | (238,000 | ) |
Wages payable | | | 0 | | | | (36,000 | ) |
Net cash (used in) / provided by operating activities | | | (201,000 | ) | | | 213,000 | |
Cash flows from investing activities: | | | | | | | | |
Sale of property, plant and equipment | | | 0 | | | | (576,000 | ) |
Sale of patent asset | | | 0 | | | | (108,000 | ) |
Net cash provided by / (used in) investing activities | | | 0 | | | | (684,000 | ) |
Cash flows from financing activities: | | | | | | | | |
Proceeds from debt financing | | | 0 | | | | 0 | |
Payments of debt financing | | | 0 | | | | (1,472,000 | ) |
Proceeds from Lincoln Park financing | | | 0 | | | | 0 | |
Proceeds from line of credit | | | 0 | | | | 0 | |
Proceeds from asset sale | | | 0 | | | | 3,000,000 | |
Repayments of line of credit | | | 0 | | | | 0 | |
Net cash provided by financing activities | | | 0 | | | | 1,538,000 | |
Net change in cash and cash equivalents | | | (201,000 | ) | | | 1057,000 | |
Cash and cash equivalents - beginning of period | | | 1,056,000 | | | | 98,000 | |
Cash and cash equivalents - end of period | | $ | 855,000 | | | $ | 1,155,000 | |
PRO FORMA – Nine Months Ended September 30, 2022
Statements of Changes in Stockholders’ Equity
(Unaudited) |
| | Common Stock | | | Additional Paid-in | | | Accumulated | | | | |
| | Shares | | | Amount | | | Capital | | | Deficit | | | Total | |
Balance – January 1, 2022 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (21,354,000 | ) | | $ | 740,000 | |
Net loss | | | | | | | | | | | | | | | (114,000 | ) | | | (114,000 | ) |
Balance – September 30, 2022 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (21,468,000 | ) | | $ | 626,000 | |
| | | | | | | | | | | | | | | | | | | | |
Balance January 1, 2021 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (23,350,000 | ) | | $ | (1,256,000 | ) |
Net income | | | | | | | | | | | | | | | 1,996,000 | | | | 1,996,000 | |
Balance – September 30, 2021 | | | 37,703,476 | | | $ | 377,000 | | | $ | 21,717,000 | | | $ | (21,354,000 | ) | | $ | 740,000 | |
PROXY
SPECIAL MEETING OF SHAREHOLDERS REGARDING THE ASSET SALE
AMERICAN BIO MEDICA CORPORATION
The undersigned shareholder of American Bio Medica Corporation, having received the Notice dated January 11, 2023 of the Special Meeting of Shareholders, hereby nominates, constitutes, appoints and authorizes Melissa A. Waterhouse and Jean Neff, or either of them with full power to act alone, as proxies with full power of substitution, for me and in my name, place and stead, to vote all the common shares of said corporation standing in my name on its books on December 22, 2022, at the Special Meeting of Shareholders to be held at 11:00 A.M. on Wednesday, February 15, 2023 at ABMC’s corporate offices located at 122 Smith Road, Kinderhook, New York 12106, or at any adjournments thereof, with all the power the undersigned would possess if personally present. This Proxy, when properly executed will be voted as designated. If no choice is specified, this proxy will be voted “FOR” each of the following:
1. To consider and vote upon a proposal to approve the Asset Purchase Agreement, dated as of December 19, 2022, between American Bio Medica Corporation (“ABMC”) and Healgen Scientific Limited Liability Company for the sale of substantially all of ABMC’s assets (the “Asset Sale”).
☐ FOR ☐ AGAINST ☐ ABSTAIN
2. To grant authority to the Board of Directors of ABMC to adjourn the 2023 Special Meeting of Shareholders, even if a quorum is present, if necessary or appropriate in the sole discretion of the Board, including to solicit additional proxies in the event that there are insufficient shares present in person or by proxy voting in favor of the Asset Sale (the “Adjournment Proposal”).
☐ FOR ☐ AGAINST ☐ ABSTAIN